[go: up one dir, main page]

WO2015150364A1 - Acides benzotriazinonebutyriques substitués et leur utilisation - Google Patents

Acides benzotriazinonebutyriques substitués et leur utilisation Download PDF

Info

Publication number
WO2015150364A1
WO2015150364A1 PCT/EP2015/056986 EP2015056986W WO2015150364A1 WO 2015150364 A1 WO2015150364 A1 WO 2015150364A1 EP 2015056986 W EP2015056986 W EP 2015056986W WO 2015150364 A1 WO2015150364 A1 WO 2015150364A1
Authority
WO
WIPO (PCT)
Prior art keywords
compound
formula
mmp
disease
copd
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2015/056986
Other languages
German (de)
English (en)
Inventor
Hartmut Beck
Volkhart Min-Jian Li
Yolanda Cancho Grande
Hannah JÖRIßEN
Andreas Timmermann
Mario Jeske
Dirk Brohm
Heinrich Meier
Michael Gerisch
Dieter Lang
Elisabeth Woltering
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer Pharma AG
Original Assignee
Bayer Pharma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Pharma AG filed Critical Bayer Pharma AG
Publication of WO2015150364A1 publication Critical patent/WO2015150364A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D253/00—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00
    • C07D253/08—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00 condensed with carbocyclic rings or ring systems

Definitions

  • the present application relates to novel substituted 4- (l, 2,3-benzotriazin-4-on-3-yl) butanoic acid derivatives, processes for their preparation, their use alone or in combinations for the treatment and / or prevention of diseases and their Use for the manufacture of medicaments for the treatment and / or prevention of diseases, in particular for the treatment and / or prevention of respiratory, pulmonary and cardiovascular diseases.
  • Human macrophage elastase belongs to the family of matrix metallo-peptidases (MMPs) and is also called human matrix metallo-peptidase 12 (hMMP-12).
  • MMPs matrix metallo-peptidases
  • hMMP-12 human matrix metallo-peptidase 12
  • the protein is increased i.a. formed by macrophages after contact with "irritating" substances or particles, activated and released.
  • Such substances and particles may, for example, be contained as impurities in suspended particles, as may be mentioned, inter alia. in cigarette smoke or industrial dusts.
  • endogenous and foreign body cell constituents and cellular debris are counted among these irritant particles, as they can be present in some cases in high concentrations in inflammatory processes.
  • the highly active enzyme is capable of degrading a variety of connective tissue proteins, e.g. primarily the protein elastin (hence the name), as well as other proteins and proteoglycans such as collagen, fibronectin, laminin, chondroitin sulfate, heparan sulfate and others.
  • This proteolytic activity of the enzyme enables macrophages to penetrate the basal membrane.
  • Elastin for example, occurs in high concentrations in all tissue types that exhibit high elasticity, e.g. in the lungs and arteries.
  • the HME plays an important role in tissue degradation (tissue remodeling).
  • the HME is an important modulator in inflammatory processes.
  • TGF- ⁇ tumor necrosis factor-alpha
  • TGF- ⁇ transforming growth factor -beta
  • MMP-12 also plays a role in host defense, particularly in the regulation of antiviral immunity, presumably through intervention in the interferon-alpha (IFN- ⁇ ) -mediated signaling pathway [A new transcriptional role-matrix matrix metalloproteinase -12 in antiviral immunity, Marchant et al., Nature Med. 20, 493-502 (2014)].
  • IFN- ⁇ interferon-alpha
  • HME plays an important role in many diseases, injuries and pathological changes, their development and / or progression an infectious or non-infectious inflammatory event and / or a proliferative and hypertrophic tissue and vascular remodeling.
  • diseases and / or damage to the lung, the kidney or the cardiovascular system or these may be cancerous diseases or other inflammatory diseases [Macrophage metalloelasta.se (MMP-12) as a target for inflammatory respiratory diseases, Lagente et al., Expert Opinion. Ther.
  • diseases and injuries of the lung are in particular the chronic obstructive pulmonary illness (COPD), the lung emphysema (lung emphysema), interstitial pulmonary diseases (interstitial lung diseases, ILD) such as the pulmonary fibrosis (ideopathic pulmonary fibrosis, IPF) and pulmonary sarcoidosis (pulmonary sareoidosis), acute lung injury (ALI), acute respiratory distress syndrome (ARDS), cystic fibrosis (CF), also called cystic fibrosis).
  • ILD interstitial lung diseases
  • ILD interstitial lung diseases
  • pulmonary fibrosis ideopathic pulmonary fibrosis, IPF
  • pulmonary sarcoidosis pulmonary sarcoidosis
  • CF cystic fibrosis
  • liver fibrosis and systemic sclerosis are mentioned as examples.
  • SIRS systemic inflammatory response syndrome
  • MODF multi-organ dysfunction
  • intravascular Coagulation dissminated intravascular coagulation, DIC
  • rheumatoid diseases for example rheumatoid arthritis, as well as chronic bowel inflammation (IBD; Crohn's disease, CD, ulcerative colitis, English, ulcerative Colitis, UC).
  • elastase-mediated pathological processes are thought to be based on a shift in the balance between free elastase (HME) and the body's own tissue inhibitor of metalloproteinase (TEVIP).
  • HME free elastase
  • TEVIP tissue inhibitor of metalloproteinase
  • oxidative bursi are prevalent in the environment of localized inflammation, further increasing protease / anti-protease imbalance [Pathogenic triad in COPD: oxidative stress, protease-antiprotease imbalance, and inflammation, Fischer et al. , Int. J. COPD 6, 413-421 (2011)].
  • MMP-2 gelatinases
  • MMP-9 collagenases
  • MMP-1 collagenases
  • MMP-8 MMP-13
  • MMP-3 stromelysins
  • MMP-7 Matrilysins
  • MMPs membrane-type MMPs
  • MT-MMPs membrane-type MMPs
  • MMP-14, MMP-15, MMP-16, MMP-17 , MMP-24, MMP-25 membrane-type MMPs
  • MMP-16, MMP-17 a characteristic domain that anchors the protein in the membrane
  • MMP-24, MMP-25 a conserved zinc-binding region in the active site of the enzyme, which is important for catalytic activity and is also found in other metalloproteins (eg a disintegrin and metalloproteinase, ADAM).
  • ADAM disintegrin and metalloproteinase
  • the complexed zinc is masked by a sulfhydryl group in the N-terminal pro-peptide domain of the protein, resulting in an enzymatically inactive pro-form of the enzyme.
  • MMPs MMPs and other similar molecules
  • ADAMs eg ADAMs
  • Numerous in vitro and preclinical in vz 'vo experiments have contributed much to a better understanding of MMPs in different disease models (eg transgenic animals, knock-out animals and genetic data from human studies).
  • the validation of a target with regard to a possible drug therapy can ultimately only take place in clinical trials on humans or patients.
  • the first generation of MMP inhibitors has been clinically studied in cancer studies.
  • the desired effect on one or more MMP targets has been masked by an undesired effect on one or more MMP anti-targets or by an undesired effect on another target site (off-target) [Validating matrix metalloproteinases as drug targets and anti Targets for Cancer Therapy, Coverall & Kleifeld, Nature Rev. Cancer 6, 227-239 (2006)].
  • Newer MMP inhibitors which are characterized by increased selectivity, have now also been clinically tested, including compounds explicitly referred to as MMP-12 inhibitors, but so far also without any conclusive clinical success. On closer examination, the inhibitors previously described as selective have also proved to be less selective.
  • test compound MMP408 shows a significantly reduced affinity for the mouse orthologous MMP-12 target: IC 50 2 nM (human MMP-12), IC50 160 nM (murine MMP-12), IC50 320 nm (rat MMP-12).
  • IC 50 2 nM human MMP-12
  • IC50 160 nM murine MMP-12
  • IC50 320 nm rat MMP-12.
  • the potency at the target MMP-12 itself is very important. With a comparatively similar pharmacokinetic profile, a highly potent compound will result in a lower therapeutic dose than a less potent compound, and generally a lower dose should be associated with a reduced likelihood of side effects. This applies in particular to the inclusion of the so-called “free fraction" (fraction unbound, f u ) of a compound which coincides with the the desired target or unwanted anti- and off-targets (the "free fraction” is defined as the available amount of a compound that is not bound to constituents of the blood plasma, which are primarily blood protein components such as albumin) , In addition to MMP selectivity, specificity is therefore of paramount importance.
  • novel macrophage elastase inhibiting agents should have high selectivity and specificity in order to be able to specifically inhibit HME.
  • a good metabolic stability of the substances is necessary (low clearance).
  • these compounds should be stable under oxidative conditions so as not to lose their inhibitory potency in disease.
  • COPD chronic obstructive pulmonary disease
  • COPD chronic obstructive pulmonary disease
  • the first symptoms of the disease usually appear from the fourth to fifth decade of life. In the following years, the shortness of breath is often aggravated and it manifests cough, associated with an extensive and sometimes purulent sputum and a stenosis breathing to a dyspnea.
  • COPD is primarily a disease of smokers: smoking is responsible for 90% of all COPD cases and 80-90% of all COPD deaths. COPD is a major medical problem and is the sixth most common cause of death worldwide. About 4-6% of those over 45 years old are affected.
  • the underlying mechanism involves immune cells that release various chemokines during the inflammatory response of the lungs.
  • neutrophilic cells and subsequently alveolar macrophages are lured to the lung connective tissue and lumen.
  • Neutrophils secrete a protease cocktail containing mainly HNE and proteinase 3.
  • Activated macrophages release the HME.
  • the protease / antipro shifted tease balance in favor of the proteases, resulting inter alia in an uncontrolled elastase activity and as a result, to an excessive degradation of the elastin of the alveolar. This tissue breakdown causes a collapse of the bronchi.
  • HME protein is associated with smoking or COPD status: detectable HME levels are lowest in non-smokers, slightly higher in former smokers and smokers, and in COPD - Patients significantly increased [Elevated MMP-12 protein levels in induced sputum from patients with COPD, Demedts et al., Thorax 61, 196-201 (2006)]. Similar data were collected with human sputum samples and bronchial alveolar washing fluid (BALF).
  • BALF bronchial alveolar washing fluid
  • HME could be detected and quantified on activated macrophages: HME amount COPD patient / smoker> COPD patient / former smoker> former smoker> Non-smoker [Patterns of airway inflammation and MMP-12 expression in smokers and ex-smokers with COPD, Babusyte et al., Respir. Res. 8, 81-90 (2007)].
  • IPD interstitial lung disease
  • IPF idiopathic pulmonary fibrosis
  • MMP-12 Macrophage Metalloelastase
  • ency Mitigates Retinal Inflammation and Pathological Angiogenesis in Ischemic Retinopathy, Li et al., PLoS ONE 7 (12), e52699 (2012)].
  • Significantly higher MMP-12 expression is also known in ischemic kidney injuries, as is the involvement of MMP-12 in other inflammatory kidney diseases [JNK signaling in human and experimental renal ischemia / reperfusion injury, Kanellis et al., Nephral. Dial. Transplant.
  • the object of the present invention was therefore the identification and provision of novel substances which act as potent, selective and specific inhibitors of human macrophage elastase (HME / MMP-12) and, as such, for the treatment and / or prevention, in particular of respiratory diseases , the lungs and the cardiovascular system are suitable.
  • HME / MMP-12 human macrophage elastase
  • WO 96/15096-A1 is 4-aryl- and 4-biaryl-substituted 4-oxobutanoic acid derivatives with inhibitory activity towards MMP-2, MMP-3, MMP-9 and, to a lesser extent, MMP-1; Because of this profile of action, the compounds have been found to be particularly suitable for the treatment of osteoarthritis, rheumatoid arthritis and tumor diseases.
  • WO 98/09940 A1 and WO 99/18079 A1 other biarylbutanoic acid derivatives have been disclosed as inhibitors of MMP-2, MMP-3 and / or MMP-13, which are suitable for the treatment of various diseases.
  • WO 00/40539 A1 claims the use of 4-biaryl-4-oxobutanoic acids for the treatment of pulmonary and respiratory diseases, based on a different degree of inhibition of MMP-2, MMP-3, MMP-8, MMP-9, MMP-12 and MMP-13 through these compounds.
  • WO 2012/014114-A1 describes 3-hydroxypropionic acid derivatives and WO 2012/038942-A1 describes oxy- or sulfonylacetic acid derivatives as dual MMP-9/12 inhibitors.
  • the compounds of the invention are characterized by a significant inhibitory activity and selectivity towards the rodent orthologous MMP-12 peptidases, such as mouse MMP-12 (also referred to as murine macrophage elastase, MME) and rat MMP-12.
  • mouse MMP-12 also referred to as murine macrophage elastase, MME
  • rat MMP-12 This allows a more complete preclinical evaluation of the substances in various established animal models of the diseases described above.
  • the present invention relates to compounds of the general formula (I)
  • R 1 represents straight-chain (C 3 -C 5) -alkyl in which a CE group may be replaced by O, straight-chain hydroxy (C 1 -C 4) -alkyl or (C 3 -C 6) -cycloalkyl which may be substituted by hydroxyl can, stands and either (a) Y stands for CH and R 2 is a substituent selected from the group fluorine, chlorine, methyl, fluoromethyl, di-fluoromethyl and trifluoromethyl, which is bonded in the designated 6- or 7-position, or (b) Y is N and
  • R 2 is hydrogen or a substituent selected from methyl and trifluoromethyl bound in the designated 6- or 7-position, as well as their salts, solvates and solvates of the salts.
  • Compounds according to the invention are the compounds of the formula (I) and their salts, solvates and solvates of the salts comprising the compounds of the formulas below and their salts, solvates and solvates of the salts and of the formula (I) encompassed by formula (I), hereinafter referred to as exemplary compounds and their salts, solvates and solvates of the salts, as far as the compounds of formula (I), the compounds mentioned below are not already salts, solvates and solvates of the salts.
  • Salts used in the context of the present invention are physiologically acceptable salts of the compounds according to the invention. Also included are salts which are not suitable for pharmaceutical applications themselves, but can be used, for example, for the isolation, purification or storage of the compounds according to the invention.
  • Physiologically acceptable salts of the compounds according to the invention include, in particular, the salts derived from customary bases, such as, by way of example and by way of preference, alkali metal salts (eg sodium and potassium salts), alkaline earth salts (eg calcium and magnesium salts), zinc salts and ammonium salts derived from ammonia or organic amines having 1 to 16 C atoms, such as, by way of example and by way of preference, ethylamine, diethylamine, triethylamine, / V, / V-diisopropylethylamine, monoethanolamine, diethanolamine, triethanolamine, tromethamine, dimethylaminoethanol, diethylaminoethanol, choline
  • solvates are those forms of the compounds according to the invention which form a complex in the solid or liquid state by coordination with solvent molecules. Hydrates are a special form of solvates in which the co- Ordination with water takes place. As solvates, hydrates are preferred in the context of the present invention.
  • the compounds of the invention may exist in different stereoisomeric forms depending on their structure, i. in the form of configurational isomers or, if appropriate, also as conformational isomers (enantiomers and / or diastereomers, including those of atropisomers).
  • the present invention therefore includes the enantiomers and diastereomers and their respective mixtures. From such mixtures of enantiomers and / or diastereomers, the stereoisomerically uniform components can be isolated in a known manner; Preferably, chromatographic methods are used for this, in particular HPLC chromatography on achiral or chiral phase.
  • enantiomerically pure in the context of the present invention is understood to mean that the relevant compound is present in an absolute configuration of the chiral center in an enantiomeric excess of more than 95%, preferably more than 98%.
  • the enantiomeric excess (ene, ee value) is calculated here by evaluating the chromatogram of a HPLC analysis on a chiral phase according to the following formula:
  • the present invention encompasses all tautomeric forms.
  • the present invention also includes all suitable isotopic variants of the compounds according to the invention.
  • An isotopic variant of a compound according to the invention is understood to mean a compound in which at least one atom within the compound according to the invention is exchanged for another atom of the same atomic number but with a different atomic mass than the atomic mass that usually or predominantly occurs in nature.
  • isotopes which can be incorporated in a compound of the invention are those of hydrogen, carbon, nitrogen, oxygen, phosphorus, sulfur, fluorine, chlorine, bromine and iodine, such as ⁇ (deuterium), ⁇ (tritium), 13 C, 14 C, 15 N, 17 0, 18 0, 32 P, 33 P, 33 S, 34 S, 35 S, 36 S, 18 F, 36 Cl, 82 Br, 123 I, 124 I, 129 I and 131 L
  • Certain isotopic variants of a compound of the invention, such as in particular those in which one or more radioactive isotopes are incorporated, may be useful, for example for the study of the mechanism of action or the distribution of active ingredient in the body; Due to the comparatively easy production and detectability, compounds labeled with 3 H or 14 C isotopes in particular are suitable for this purpose.
  • isotopes such as from Deuterium
  • isotopes such as from Deuterium
  • modifications of the compounds of the invention may therefore optionally also constitute a preferred embodiment of the present invention.
  • Isotopic variants of the compounds according to the invention can be prepared by generally customary processes known to the person skilled in the art, for example by the methods described below and the rules reproduced in the exemplary embodiments by using corresponding isotopic modifications of the respective reagents and / or starting compounds.
  • the present invention also includes prodrugs of the compounds of the invention.
  • prodrugs here denotes compounds which may themselves be biologically active or inactive, but are converted during their residence time in the body by, for example, metabolic or hydrolytic routes to compounds of the invention.
  • the present invention comprises, as prodrugs, hydrolyzable ester derivatives of the carboxylic acids of the formula (I) according to the invention.
  • esters which can be hydrolyzed in physiological media, under the conditions of the biological assays described below, and in particular in vivo enzymatically or chemically to the free carboxylic acids, as the main biologically active compounds.
  • preference is given to (C 1 -C -alkyl esters in which the alkyl group may be straight-chain or branched.)
  • Particular preference is given to methyl, ethyl or ethyl-butyl esters.
  • (C 1 -C 5) -alkyl in the context of the invention is a straight-chain saturated alkyl radical having 3 to 5 carbon atoms. Examples which may be mentioned are: n-propyl, n-butyl and n-pentyl.
  • Hydroxy-C 1 -C 4 -alkyl in the context of the invention is a straight-chain saturated alkyl radical having 1 to 4 carbon atoms which terminally carries a hydroxy group as substituent.
  • hydroxymethyl 2-hydroxyethyl, 3-hydroxypropyl and 4-hydroxybutyl.
  • (C 3 -C 6) -cycloalkyl is a monocyclic saturated cycloalkyl group having 3 to 6 ring carbon atoms. Examples which may be mentioned are: cyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl. In the context of the present invention, the meaning is independent of each other for all radicals which occur repeatedly. If radicals are substituted in the compounds according to the invention, the radicals can, unless otherwise specified, be monosubstituted or polysubstituted. Substitution with one or two identical or different substituents is preferred. Particularly preferred is the substitution with a substituent.
  • a particular embodiment of the present invention comprises compounds of the formula (I) in which
  • R 1 is (C 3 -C 6 ) -cycloalkyl, and their salts, solvates and solvates of the salts.
  • Another particular embodiment of the present invention comprises compounds of the formula (I) in which
  • R 2 is a substituent selected from the group consisting of chlorine, methyl and trifluoromethyl, which is bonded in the designated 6- or 7-position, and their salts, solvates and solvates of the salts.
  • Another particular embodiment of the present invention comprises compounds of the formula (I) in which
  • R 2 is hydrogen, and their salts, solvates and solvates of the salts.
  • R 1 is n-butyl, hydroxymethyl, methoxymethyl, cyclopropyl or cyclopentyl and either (a)
  • R 2 is a substituent selected from methyl and trifluoromethyl bound in the designated 6- or 7-position, or (b)
  • R 2 is hydrogen, and their salts, solvates and solvates of the salts.
  • R 1 is n-butyl or cyclopentyl
  • R 2 is a substituent selected from methyl and trifluoromethyl bound in the designated 6- or 7-position, as well as their salts, solvates and solvates of the salts.
  • Another object of the invention is a process for the preparation of the compounds of the invention, characterized in that di-ieri.-butyl- (2-hydroxyethyl) malonate of the formula
  • R 1 has the abovementioned meaning and represents a leaving group such as, for example, chlorine, bromine, iodine, mesylate, triflate or tosylate, a compound of the formula (VI)
  • PG is a temporary protecting group such as acetyl or benzoyl and a leaving group such as chlorine, bromine, iodine, mesylate, triflate or
  • reaction (II) + (III) -> (IV) is carried out under the usual conditions of a "Mitsunobu reaction" in the presence of a phosphine and an azodicarboxylate [see, eg, DL Hughes, Org. Reactions 42, 335 (1992). ; DL Hughes, Org. Prep. Proced. Int.
  • phosphine components are triphenylphosphine, tri-n-butylphosphine, 1,2-bis (diphenylphosphino) ethane (DPPE), diphenyl (2-pyridyl) phosphine, (4-dimethylaminophenyl) diphenylphosphine or tris (4-dimethylaminophenyl ) phosphine.
  • DPPE 1,2-bis (diphenylphosphino) ethane
  • diphenyl (2-pyridyl) phosphine diphenyl (2-pyridyl) phosphine
  • (4-dimethylaminophenyl) diphenylphosphine or tris (4-dimethylaminophenyl ) phosphine.
  • azodicarboxylate can for example, diethyl azodicarboxylate (DEAD), diisopropyl azodicarboxylate (DIAD), ⁇ -tert-butyl azodicarboxylate, / V, / V, / VW-tetramethyl azodicarboxamide (TMAD), 1,1'-azodicarbonyl di-piperidine (ADDP) or 4,7- Dimethyl-3,5,7-hexahydro-l, 2,4,7-tetrazocine-3,8-dione (DHTD) can be used.
  • DEAD diethyl azodicarboxylate
  • DIAD diisopropyl azodicarboxylate
  • TMAD ⁇ -tert-butyl azodicarboxylate
  • TMAD 1,1'-azodicarbonyl di-piperidine
  • DHTD 4,7- Dimethyl-3,5,7-hexahydro-l, 2,4,7-tetrazo
  • Inert solvents for the reaction ( ⁇ ) + (III) - (IV) are, for example, ethers, such as diethyl ether, diisopropyl ether, methyl ieri-butyl ether, tetrahydrofuran, 1,4-dioxane, 1,2-dimethoxyethane or Bis (2-methoxyethyl) ether, hydrocarbons such as benzene, toluene, xylene, pentane, hexane or cyclohexane, or polar aprotic solvents such as acetonitrile, butyronitrile, dimethyl sulfoxide (DMSO), N, N-dimethylformamide (DMF), N, N-dimethylacetamide (DMA) , JV, JV'-dimethylpropyleneurea (DMPU) or / V-methylpyrrolidinone (NMP). It is also possible to use mixtures of such solvents. Preference
  • reaction (II) + ( ⁇ ) - (IV) is usually carried out in a temperature range from -20 ° C to + 60 ° C, preferably at 0 ° C to + 40 ° C.
  • the use of a microwave oven may be advantageous in this reaction.
  • Suitable bases for the alkylation reactions (IV) + (V) -> (VI) and (IV) + (VII) -> (VIII) are particularly suitable alkali metal alcoholates, such as sodium or potassium methoxide, sodium or potassium ethoxide or sodium or Potassium ieri.-butoxide, alkali metal hydrides such as sodium or potassium hydride, amides such as lithium diisopropylamide or lithium, sodium or potassium bis (trimethylsilyl) amide, or conventional organometallic bases such as phenyllithium or n-, sec- or ieri.-butyllithium , Preferably, sodium hydride or potassium ieri.-butoxide is used.
  • Suitable inert solvents for process steps (IV) + (V) -> (VI) and (IV) + (VII) -> (VIII) are, for example, ethers, such as diethyl ether, diisopropyl ether, methyl ieri-butyl ether, tetrahydrofuran, 1 , 4-dioxane, 1,2-dimethoxyethane or bis (2-methoxyethyl) ether, hydrocarbons such as benzene, toluene, xylene, pentane, hexane or cyclohexane, or dipolar aprotic solvents such as acetonitrile, butyronitrile, A 1 -dimethylformamide ( DMF), dimethylacetamide (DMA), N, N'-dimethylpropyleneurea (DMPU), N-methylpyrrolidinone (NMP) or dimethyl sulfoxide (DMSO).
  • ethers such as die
  • a 1 -dimethylformamide (DMF) is used.
  • the reactions (IV) + (V) -> (VI) and (IV) + (VII) -> (VIII) are generally in a temperature range from -70 ° C to + 100 ° C, preferably at 0 ° C to + 60 ° C performed.
  • the cleavage of an acetyl or benzoyl protective group PG in process step (VIII) - (IX) is preferably carried out with the aid of an alkali metal hydroxide, such as lithium, sodium or potassium hydroxide, or an alkali metal alkoxide, such as sodium or potassium methoxide or sodium or potassium.
  • Particularly suitable solvents for this reaction are water, alcohols such as methanol, ethanol, n-propanol or isopropanol, ethers such as tetrahydrofuran, 1,4-dioxane or 1,2-dimethoxyethane, or mixtures of these solvents.
  • ethers such as tetrahydrofuran, 1,4-dioxane or 1,2-dimethoxyethane, or mixtures of these solvents.
  • Sodium methoxide in a solvent mixture of methanol and tetrahydrofuran is preferably used for the cleavage.
  • the reaction is generally carried out in a temperature range from 0 ° C to + 60 ° C.
  • a silyl group such as trimethylsilyl, triethylsilyl, triisopropylsilyl, ieri-butyldimethylsilyl or tert-butyldiphenylsilyl may be used as the temporary hydroxy-protecting group PG in (VII).
  • Their cleavage in process step (VIII) - (IX) is carried out in the usual way with the aid of a fluoride such as tetrabutylammonium fluoride (TBAF).
  • TBAF tetrabutylammonium fluoride
  • Another possibility is the use of benzyl as protecting group PG; this can be removed by hydrogenolysis in a known way [see also TW Greene and PGM Wuts, Protective Croups in Organic Synthesis, Wiley, New York, 1999].
  • Suitable bases for the alkylation reaction (IX) + (X) - (VI) are in particular alkali metal carbonates such as lithium, sodium, potassium or cesium carbonate, alkali metal alcoholates such as sodium or potassium methoxide, sodium or potassium ethoxide or sodium or potassium -iati-butoxide, or alkali hydrides such as sodium or potassium hydride.
  • alkali metal carbonates such as lithium, sodium, potassium or cesium carbonate
  • alkali metal alcoholates such as sodium or potassium methoxide, sodium or potassium ethoxide or sodium or potassium -iati-butoxide
  • alkali hydrides such as sodium or potassium hydride.
  • potassium carbonate is used.
  • Inert solvents for this reaction are, for example, ethers, such as diethyl ether, diisopropyl ether, methyl tert. -b tyl ether, tetrahydrofuran, 1,4-dioxane, 1,2-dimethoxyethane or bis (2-meth- oxyethyl) ether, hydrocarbons such as benzene, toluene, xylene, pentane, hexane or cyclohexane, or polar aprotic solvents such as acetone , Methyl ethyl ketone, ethyl acetate, acetonitrile, butyronitrile, dimethyl sulfoxide (DMSO), N, N-dimethylformamide (DMF), N, N-dimethylacetamide (DMA), N, N'-dimethylpropylurea (DMPU) or N-methylpyrrolidinone (NMP
  • reaction (IX) + (X) - (VI) is generally carried out in a temperature range from 0 ° C to + 100 ° C.
  • the ester cleavage and decarboxylation to the monocarboxylic acid in process step (VI) - (I) is achieved by treatment of the diester with a strong acid such as trifluoroacetic acid or hydrogen chloride and subsequent heating of the intermediately formed dicarboxylic acid.
  • the reaction can be carried out in a one-pot process, without isolation of the intermediate, or in two stages be performed.
  • ester cleavage in the case of the reaction with trifluoroacetic acid, preference is given to using dichloromethane and, in the case of reaction with hydrogen chloride, preferably 1,4-dioxane, in each case under anhydrous conditions, as solvent.
  • the ester cleavage is usually carried out in a temperature range from 0 ° C to + 30 ° C.
  • the subsequent decarboxylation is usually carried out in a temperature range from + 100 ° C. to + 150 ° C. in a correspondingly high-boiling inert solvent;
  • 1,4-dioxane is used for this purpose.
  • the process steps described above may be carried out at normal, elevated or reduced pressure (for example in the range from 0.5 to 5 bar); In general, one works at normal pressure.
  • the separation of stereoisomers (enantiomers and / or diastereomers) of the compounds of the formula (I) according to the invention can be achieved by customary methods known to the person skilled in the art. Preferably, chromatographic methods for achiral or chiral separation phases are used for this purpose. Alternatively, it is also possible to carry out a separation via diastereomeric salts of the carboxylic acids of the formula (I) with chiral amine bases.
  • the 1,2,3-triazine-4 (3i7) -one derivatives of the formula (II) can be prepared in a simple manner by treatment of ori / amino aminocarboxamides of the formula (XI)
  • R 2 and Y have the meanings given above, accessible with sodium nitrite in aqueous hydrochloric acid [see, eg, D. Fernandez-Forner et al., Tetrahedron 47 (42), 8917-8930 (1991)].
  • the compounds of the formula (V) can be prepared starting from compounds of the formula (II) or (II)
  • the compounds according to the invention have valuable pharmacological properties and can be used for the prevention and treatment of diseases in humans and animals.
  • the compounds of the invention are potent, non-reactive and selective inhibitors of human macrophage elastase (HME / hMMP-12), which have a significantly improved profile of potency and selectivity compared to the compounds known in the art. Moreover, many of the compounds of the invention to a low in vz 'iro clearance and a good metabolic stability. This property profile Overall, a low dosability and, as a result of the more targeted mode of action, a reduced risk of the occurrence of undesirable side effects in the therapy can be expected for the compounds according to the invention.
  • HME / hMMP-12 human macrophage elastase
  • the compounds according to the invention are therefore particularly suitable for the treatment and / or prevention of diseases and pathological processes, in particular those in which, in the course of an infectious or non-infectious inflammatory event and / or a tissue or vascular remodeling, the macrophage elastase (HME / hMMP-12).
  • these include, in particular, diseases of the respiratory tract and the lungs, such as chronic obstructive pulmonary disease (COPD), asthma and the group of interstitial lung diseases (ILD), and diseases of the cardiovascular system, such as arteriosclerosis and aneurysms ,
  • COPD chronic obstructive pulmonary disease
  • ILD interstitial lung diseases
  • arteriosclerosis and aneurysms diseases of the cardiovascular system, such as arteriosclerosis and aneurysms
  • COPD chronic obstructive pulmonary disease
  • pulmonary emphysema e.g. Cigarette smoke-induced pulmonary emphysema, chronic bronchitis (CB), pulmonary hypertension in COPD (PH-COPD), bronchiectasis (BE) and combinations thereof, especially in acute exacerbating stages of the disease (AE-COPD).
  • CB chronic bronchitis
  • PH-COPD pulmonary hypertension in COPD
  • BE bronchiectasis
  • AE-COPD acute exacerbating stages of the disease
  • Types of asthma include asthmatic diseases of varying degrees of severity with intermittent or persistent history, such as refractory asthma, bronchial asthma, allergic asthma, intrinsic asthma, extrinsic asthma, and medication-induced or dust-induced asthma.
  • interstitial lung diseases includes idiopathic pulmonary fibrosis (IPF), pulmonary sarcoidosis and acute interstitial pneumonia, non-specific interstitial pneumonia, lymphoid interstitial pneumonia, respiratory bronchiolitis with interstitial lung disease, cryptogenic organizing pneumonia, desquamative interstitialile Pneumonia and non-classifiable idiopathic interstitial pneumonia, granulomatous interstitial lung disease, interstitial lung disease of known cause and other interstitial lung diseases of unknown cause.
  • IPF idiopathic pulmonary fibrosis
  • pulmonary sarcoidosis and acute interstitial pneumonia
  • non-specific interstitial pneumonia non-specific interstitial pneumonia
  • lymphoid interstitial pneumonia lymphoid interstitial pneumonia
  • respiratory bronchiolitis with interstitial lung disease cryptogenic organizing pneumonia
  • desquamative interstitialile Pneumonia desquamative interstitialile Pneumonia and non-classifiable idiopathic interstitial
  • the compounds of the invention may also be used for the treatment and / or prevention of other respiratory and pulmonary diseases, such as pulmonary arterial hypertension (PAH) and other forms of pulmonary hypertension (PH), bronchiolitis obliterans syndrome (BOS), of acute respiratory syndrome (ARDS), acute lung injury (ALI), alpha-1-antitrypsin deficiency (AATD) and cystic fibrosis (CF), various types of bronchitis (chronic bronchitis, infectious bronchitis, eosinophilic bronchiectasis, pneumonia, farmer's lung and related diseases, infectious and non-infectious cough and cold diseases (chronic inflammatory cough, iatrogenic cough), inflammations of the nose (including rhinitis, vasomotor rhinitis and season-dependent allergic rhinitis, eg hay fever). fen) and polyps.
  • PH pulmonary arterial hypertension
  • PH bronchiolitis obliterans syndrome
  • the group of diseases of the cardiovascular system includes, in particular, arteriosclerosis and its secondary diseases, such as, for example, Stroke in arteriosclerosis of the cervical arteries (carotid arteriosclerosis), myocardial infarction in arteriosclerosis of the coronary arteries, peripheral arterial occlusive disease (PAOD) due to arteriosclerosis of the leg arteries, as well as aneurysms, in particular aneurysms of the aorta, e.g.
  • arteriosclerosis and its secondary diseases such as, for example, Stroke in arteriosclerosis of the cervical arteries (carotid arteriosclerosis), myocardial infarction in arteriosclerosis of the coronary arteries, peripheral arterial occlusive disease (PAOD) due to arteriosclerosis of the leg arteries, as well as aneurysms, in particular aneurysms of the aorta, e.g.
  • Atherosclerosis hypertension, injuries and inflammations, infections (eg rheumatic fever, syphilis, Lyme disease), congenital connective tissue weaknesses (eg in Marfan syndrome and Ehlers-Danlos syndrome) or as a result of a volume burden of the aorta in congenital heart defects with right-left shunt or a shunt-dependent perfusion of the lungs, as well as aneurysms on coronary vessels in the course of a disease in Kawasaki syndrome and in brain areas in patients with a congenital aortic valve malformation.
  • infections eg rheumatic fever, syphilis, Lyme disease
  • congenital connective tissue weaknesses eg in Marfan syndrome and Ehlers-Danlos syndrome
  • the compounds of the invention may also be used for the treatment and / or prevention of other cardiovascular diseases such as hypertension, heart failure, coronary heart disease, stable and unstable angina pectoris, renal hypertension, peripheral and cardial vascular diseases, arrhythmias, atrial arrhythmias and of the ventricles as well as conduction disorders such as atrio-ventricular blockades of grade I-III, supraventricular tachyarrhythmia, atrial fibrillation, atrial flutter, ventricular fibrillation, ventricular flutter, ventricular tachyarrhythmia, torsades de pointes tachycardia, extrasystoles of the atrium and ventricle, atrioventricular extrasystoles, Sick sinus syndrome, syncope, AV nodal reentry tachycardia, Wolff-Parkinson-White syndrome, acute coronary syndrome (ACS), autoimmune heart disease (pericarditis, endocarditis, valvolitis, aortitis,
  • cardiac insufficiency includes both acute and chronic manifestations of heart failure, as well as specific or related forms thereof, such as acute decompensated heart failure, right heart failure, left heart failure, global insufficiency, ischemic cardiomyopathy, dilated cardiomyopathy, hypertrophic cardiomyopathy, idiopathic cardiomyopathy, congenital heart defects
  • Heart valve failure heart failure in heart valve defects, mitral valve stenosis, mitral valve insufficiency, aortic valve stenosis, aortic valve insufficiency, tricuspid stenosis, tricuspid insufficiency, pulmonary valve stenosis, pulmonary valve insufficiency, combined valvular heart failure, myocarditis, chronic myocarditis, acute myocarditis, viral myocarditis, diabetic heart failure, alcoholic cardiomyopathy cardiac storage disorders as well as diastolic and systolic heart failure.
  • kidney diseases in particular renal insufficiency and kidney failure.
  • renal insufficiency and renal failure include both acute and chronic manifestations thereof as well as underlying or related renal diseases such as renal hypoperfusion, intradialytic hypotension, obstructive uropathy, glomerulopathies, glomerulonephritis, acute glomerulonephritis, glomerulosclerosis, tubulointerstitial disorders, nephropathic disorders such as primary and congenital kidney disease, nephritis, immunological kidney diseases such as renal transplant rejection and Alport syndrome, immune complex-induced kidney disease, toxic-induced nephropathy, contrast-induced nephropathy, diabetic and non-diabetic nephropathy, pyelonephritis, renal cysts, nephrosclerosis, hypertensive Nephrosclerosis and nephrotic syndrome, which are abnormally elevated diagnostic
  • the present invention also encompasses the use of the compounds of the invention for the treatment and / or prevention of sequelae of renal insufficiency, such as hypertension, pulmonary edema, heart failure, uremia, anemia, electrolyte imbalances (eg, hyperkalemia, hyponatremia) and disorders in bone and carbohydrate metabolism.
  • sequelae of renal insufficiency such as hypertension, pulmonary edema, heart failure, uremia, anemia, electrolyte imbalances (eg, hyperkalemia, hyponatremia) and disorders in bone and carbohydrate metabolism.
  • the compounds according to the invention are suitable for the treatment and / or prevention of diseases of the genitourinary system, such as benign prostatic syndrome (BPS), benign prostatic hyperplasia (BPH), benign prostatic hyperplasia (BPE), bladder emptying disorders (BOO), lower urinary tract syndromes (LUTS) , neurogenic overactive bladder (OAB), incontinence such as mixed, urgency, stress or overflow incontinence (MUI, UUI, SUI, OUI), pelvic pain, as well as erectile dysfunction and female sexual dysfunction.
  • BPS benign prostatic syndrome
  • BPH benign prostatic hyperplasia
  • BPE benign prostatic hyperplasia
  • BOO bladder emptying disorders
  • LUTS lower urinary tract syndromes
  • OAB neurogenic overactive bladder
  • incontinence such as mixed, urgency, stress or overflow incontinence (MUI, UUI, SUI, OUI), pelvic pain, as well as erectile dysfunction and female sexual dysfunction.
  • the compounds of the invention have anti-inflammatory activity and can therefore be used as anti-inflammatory agents for the treatment and / or prevention of sepsis (SIRS), multiple organ failure (MODS, MOF), inflammatory diseases of the kidney, chronic intestinal inflammation (IBD, Crohn's disease, ulcerative colitis ), Pancreatitis, peritonitis, cystitis, urethritis, prostatitis, epidymitis, oophoritis, salpingitis, vulvovaginitis, rheumatoid diseases, inflammatory diseases of the central nervous system, multiple sclerosis, inflammatory skin diseases, and inflammatory ocular diseases.
  • SIRS sepsis
  • MODS multiple organ failure
  • MOF multiple organ failure
  • IBD chronic intestinal inflammation
  • IBD chronic intestinal inflammation
  • Crohn's disease chronic intestinal inflammation
  • ulcerative colitis ulcerative colitis
  • Pancreatitis peritonitis
  • cystitis cystitis
  • urethritis prostatitis
  • the compounds according to the invention are furthermore suitable for the treatment and / or prevention of fibrous diseases of the internal organs, such as, for example, the lung, the heart, the kidney, the bone marrow and in particular the liver, as well as dermatological fibroses and fibroid diseases of the eye .
  • the term fibrotic disorders encompasses in particular such diseases as liver fibrosis, liver cirrhosis, pulmonary fibrosis, endomyocardial fibrosis, nephropathy, glomerulonephritis, interstitial kidney fibrosis, fibrotic damage as a result of diabetes, bone marrow fibrosis, peritoneal fibrosis and similar fibrotic disorders, scleroderma, morphea, Keloids, hypertrophic scarring, nevi, diabetic retinopathy, proliferative vitroretinopathy and connective tissue disorders (eg sarcoidosis).
  • the compounds of the invention may also be used to promote wound healing,
  • the compounds of the invention may be used for the treatment and / or prevention of anemias, such as hemolytic anemias, especially hemoglobinopathies such as sickle cell anemia and thalassemias, megaloblastic anemias, iron deficiency anemias, acute blood loss anemia, crowding anaemias and aplastic anemias.
  • anemias such as hemolytic anemias, especially hemoglobinopathies such as sickle cell anemia and thalassemias, megaloblastic anemias, iron deficiency anemias, acute blood loss anemia, crowding anaemias and aplastic anemias.
  • the compounds of the invention are also useful in the treatment of cancers such as skin cancer, brain tumors, breast cancer, bone marrow tumors, leukemias, liposarcomas, carcinomas of the gastrointestinal tract, liver, pancreas, lung, kidney, ureter, prostate and genital tract, and of malignant tumors of the lymphoproliferative system, such as Hodgkin's and Non-Hodgkin's Lymphoma.
  • cancers such as skin cancer, brain tumors, breast cancer, bone marrow tumors, leukemias, liposarcomas, carcinomas of the gastrointestinal tract, liver, pancreas, lung, kidney, ureter, prostate and genital tract
  • malignant tumors of the lymphoproliferative system such as Hodgkin's and Non-Hodgkin's Lymphoma.
  • the compounds according to the invention can be used for the treatment and / or prevention of lipid metabolism disorders and dyslipidemias (hypolipoproteinemia, hypertriglyceridemia, hyperlipidemia, combined hyperlipidemias, hypercholesterolemia, abetalipoproteinemia, sitosterolemia), xanthomatosis, Tangier's disease, obesity, obesity , metabolic disorders (metabolic syndrome, hyperglycemia, insulin-dependent diabetes, non-insulin-dependent diabetes, gestational diabetes, hyperinsulinemia, insulin resistance, glucose intolerance and diabetic sequelae such as retinopathy, nephropathy and neuropathy), diseases of the gastrointestinal tract and the abdomen (Glositis, gingivitis, periodontitis, esophagitis, eosinophilic gastroenteritis, mastocytosis, Crohn's disease, colitis, proctitis, pruritis ani, diarrhea, celiac disease, hepatitis, liver fibrosis, liver cirr
  • arthropathies such as arthropathy deformans, arthropathy neuropathic, ovarian arthropathy, arthropathy psoriatica and arthropathy tabica, systemic Sclerosis, multiple forms of inflammatory myopathies such as myopathy epidemica, myopathy fibrosa, myopathy myoglobinurica, myopathy ossificans, myopathy ossificans neurotica, myopathy ossificans progressiva multiplex, myopathy purulenta, myopathy rheumatica, myopathy trichinosa, myopathy tropica and myopathy typhosa, as well as the gtther syndrome and Münchmeyer syndrome), inflammatory arterial changes (various forms of arteritis such as endarteritis, mesarteritis, periarteritis, panarteritis, rheumatoid arthritis, arteritis deformus, temporal arteritis, cranial arteritis, giganto
  • the compounds according to the invention are particularly suitable for the treatment and / or prevention of respiratory and pulmonary diseases, especially chronic obstructive pulmonary disease (COPD), in particular pulmonary emphysema, chronic bronchitis (CB), pulmonary Hypertension in COPD (PH-COPD) and bronchiectasis (BE) as well as combinations of these diseases, especially in acute exacerbating stages of COPD disease (AE-COPD), asthma and interstitial lung diseases, in particular idiopathic pulmonary fibrosis ( IPF) and pulmonary sarcoidosis, diseases of the cardiovascular system, in particular atherosclerosis, especially carotid arteriosclerosis, as well as viral myocarditis, cardiomyopathy and aneurysms, including their sequelae such as stroke, myocardial infarction and peripheral artery disease (PAOD), as well as chronic kidneys - diseases and the Alport syndrome.
  • COPD chronic obstructive pulmonary disease
  • CB chronic bronchit
  • treatment includes inhibiting, delaying, arresting, alleviating, attenuating, restraining, reducing, suppressing, restraining or curing a disease, a disease, a disease, an injury or a medical condition , the unfolding, the course or progression of such conditions and / or the symptoms of such conditions.
  • therapy is understood to be synonymous with the term “treatment”.
  • prevention means the avoidance or reduction of the risk, a disease, a disease, a disease, an injury or a health disorder, a development or a Progression of such conditions and / or to get, experience, suffer or have the symptoms of such conditions.
  • the treatment or the prevention of a disease, a disease, a disease, an injury or a health disorder can be partial or complete.
  • Another object of the present invention is the use of the compounds of the invention for the treatment and / or prevention of diseases, in particular the aforementioned diseases.
  • Another object of the present invention is the use of the compounds of the invention for the manufacture of a medicament for the treatment and / or prevention of diseases, in particular the aforementioned diseases.
  • Another object of the present invention is a pharmaceutical composition containing at least one of the compounds of the invention, for the treatment and / or prevention of diseases, in particular the aforementioned diseases.
  • Another object of the present invention is the use of the compounds of the invention in a method for the treatment and / or prevention of diseases, in particular the aforementioned diseases.
  • Another object of the present invention is a method for the treatment and / or prevention of diseases, in particular the aforementioned diseases, using an effective amount of at least one of the compounds of the invention.
  • the compounds according to the invention can be used alone or as needed in combination with one or more other pharmacologically active substances, as long as this combination does not lead to undesired and unacceptable side effects.
  • Another object of the present invention are therefore pharmaceutical compositions containing at least one of the compounds of the invention and one or more other active ingredients, in particular for the treatment and / or prevention of the aforementioned diseases.
  • Suitable combination active substances for this purpose are by way of example and preferably mentioned: ⁇ anti-obstructive / bronchodilatory agents, as used, for example, for the treatment of chronic obstructive pulmonary disease (COPD) or of bronchial asthma.
  • COPD chronic obstructive pulmonary disease
  • beta-adrenergic receptor agonists beta-mimetics
  • the inhaled anti-muscarinic substances and the PDE 4 inhibitors organic nitrates and NO donors such as sodium nitroprusside, nitroglycerin, isosorbide mononitrate, isosorbide dinitrate, molsidomine or SIN-1, and inhaled NO;
  • cGMP cyclic guanosine monophosphate
  • cAMP cyclic adenosine monophosphate
  • PDE phosphodiesterases
  • PDE 4 inhibitors such as roflumilast
  • PDE 5 inhibitors such as sildenafil, vardenafil, tadalafil, uddenafil, dasantafil, avanafil, mirodenafil or lodenafil;
  • sGC soluble guanylate cyclase
  • sGC soluble guanylate cyclase
  • HNE human neutrophil elastase
  • Sivelastat Sivelastat
  • DX-890 Reltran
  • Prostacyclin analogs and IP receptor agonists such as by way of example and preferably iloprost, beraprost, treprostinil, epoprostenol or NS-304;
  • Endothelin receptor antagonists such as by way of example and preferably bosentan, darusentan, ambrisentan or sitaxsentan; anti-inflammatory, immunomodulatory, immunosuppressant and / or cytotoxic agents, by way of example and preferably from the group of systemic or inhaled corticosteroids, and acetylcysteine, montelukast, azathioprine, cyclophosphamide, hydroxycarbamide, azithromycin, IFN- ⁇ , pirfenidone or etanercept;
  • Antifibrotic agents such as, by way of example and by way of preference, lysophosphatidic acid receptor 1 (LPA-1) antagonists, lysyl oxidase (LOX) inhibitors, lysyl oxidase like 2 inhibitors, vasoactive intestinal peptide (VIP), VIP analogs, ⁇ v ⁇ 6 Integrin antagonists, cholchicine, IFN- ⁇ , D-
  • Antihypertensive agents by way of example and preferably from the group of calcium antagonists, angiotensin AII antagonists, ACE inhibitors, vasopeptidase inhibitors, endothelin antagonists, renin inhibitors, alpha-receptor blockers, beta-receptor blockers, Mineralocorticoid receptor antagonists and diuretics;
  • the signal transduction cascade inhibiting compounds by way of example and preferably from the group of kinase inhibitors, in particular from the group of tyrosine kinase and / or serine / threonine kinase inhibitors, such as by way of example and preferably nintedanib, dasatinib, nilotinib, bosutinib, regorafenib, sorafenib, sunitinib , Cediranib, axitinib, telatinib, imatinib, brivanib, pazo
  • Antagonists of growth factors, cytokines and chemokines by way of example and preferably antagonists of TGF- ⁇ , CTGF, IL-1, IL-4, IL-5, IL-6, IL-8, IL-13 and integrins;
  • the Rho kinase inhibiting compounds such as exemplified and preferably Fasudil, Y-27632, SLx-2119, BF-66851, BF-66852, BF-66853, KI-23095 or BA-1049;
  • chemotherapeutic agents as e.g. used for the treatment of neoplasms of the lungs or other organs; and / or antibiotics, in particular from the group of fluoroquinolonecarboxylic acids, such as by way of example and preferably ciprofloxacin or moxifloxacin.
  • the compounds according to the invention are administered in combination with a beta-adrenergic receptor agonist such as, for example and preferably, albuterol, isoproterenol, metaproterenol, terbutaline, fenoterol, formoterol, repro sterol, salbutamol or salmeterol.
  • a beta-adrenergic receptor agonist such as, for example and preferably, albuterol, isoproterenol, metaproterenol, terbutaline, fenoterol, formoterol, repro sterol, salbutamol or salmeterol.
  • the compounds according to the invention are administered in combination with an anti-muscarinergic substance, such as by way of example and preferably ipratropium bromide, tiotropium bromide or oxitropium bromide.
  • an anti-muscarinergic substance such as by way of example and preferably ipratropium bromide, tiotropium bromide or oxitropium bromide.
  • the compounds according to the invention are administered in combination with a corticosteroid, such as by way of example and preferably prednisone, prednisolone, methylprednisolone, triamcinolone, dexamethasone, beclomethasone, betamethasone, flunisolide, budesonide or fluticasone.
  • a corticosteroid such as by way of example and preferably prednisone, prednisolone, methylprednisolone, triamcinolone, dexamethasone, beclomethasone, betamethasone, flunisolide, budesonide or fluticasone.
  • Antithrombotic agents are preferably understood as meaning compounds from the group of platelet aggregation inhibitors, anticoagulants and profibrinolytic substances.
  • the compounds according to the invention are administered in combination with a platelet aggregation inhibitor, such as, by way of example and by way of preference, aspirin, clopidogrel, ticlopidine or dipyridamole.
  • a platelet aggregation inhibitor such as, by way of example and by way of preference, aspirin, clopidogrel, ticlopidine or dipyridamole.
  • the compounds according to the invention are administered in combination with a thrombin inhibitor such as, by way of example and by way of preference, ximelagatran, melagatran, dabigatran, bivalirudin or Clexane.
  • a thrombin inhibitor such as, by way of example and by way of preference, ximelagatran, melagatran, dabigatran, bivalirudin or Clexane.
  • the compounds according to the invention are administered in combination with a GPIIb / nia antagonist, such as, by way of example and by way of preference, tirofiban or abciximab.
  • a GPIIb / nia antagonist such as, by way of example and by way of preference, tirofiban or abciximab.
  • the compounds according to the invention are used in combination with a factor Xa inhibitor, such as by way of example and preferably rivaraban, apixaban, fidexaban, razaxaban, fondaparinux, idraparinux, DU-176b, PMD-3112, YM-150, KFA -1982, EMD-503982, MCM-17, MLN-1021, DX 9065a, DPC 906, JTV 803, SSR-126512 or SSR-128428.
  • a factor Xa inhibitor such as by way of example and preferably rivaraban, apixaban, fid
  • the compounds according to the invention are administered in combination with heparin or a low molecular weight (LMW) heparin derivative.
  • LMW low molecular weight
  • the compounds according to the invention are administered in combination with a vitamin K antagonist, such as by way of example and preferably coumarin.
  • antihypertensive agents are preferably compounds from the group of calcium antagonists, angiotensin AII antagonists, ACE inhibitors, endothelin antagonists, renin inhibitors, alpha-receptor blocker, beta-receptor blocker, mineralocorticoid receptor Antagonists and diuretics understood.
  • the compounds according to the invention are administered in combination with a calcium antagonist, such as, by way of example and by way of preference, nifedipine, amlodipine, verapamil or diltiazem.
  • a calcium antagonist such as, by way of example and by way of preference, nifedipine, amlodipine, verapamil or diltiazem.
  • the compounds according to the invention are administered in combination with an alpha-1-receptor blocker, such as by way of example and preferably prazosin.
  • the compounds according to the invention are used in combination with a beta-receptor blocker, such as by way of example and preferably propranolol, atenolol, timolol, pindolol, alprenolol, oxprenolol, penbutolol, bupranolol, metipropanol, nadolol, mepindolol, carazalol, Sotalol, metoprolol, betaxolol, celiprolol, bisoprolol, Carteolol, esmolol, labetalol, carvedilol, adaprolol, landiolol, nebivolol, epanolol or bucine dolol administered.
  • a beta-receptor blocker such as by way of example and preferably propranolol, atenolol, timolol
  • the compounds according to the invention are administered in combination with an angiotensin AII antagonist, such as by way of example and preferably losartan, candesartan, valsartan, telmisartan or embursatan.
  • an angiotensin AII antagonist such as by way of example and preferably losartan, candesartan, valsartan, telmisartan or embursatan.
  • the compounds according to the invention are administered in combination with an ACE inhibitor such as, by way of example and by way of preference, enalapril, captopril, lisinopril, ramipril, delapril, fosinopril, quinopril, perindopril or trandopril.
  • an endothelin antagonist such as, by way of example and by way of preference, bosentan, darusentan, ambrisentan or sitaxsentan.
  • the compounds of the invention are administered in combination with a renin inhibitor, such as by way of example and preferably aliskiren, SPP-600 or SPP-800.
  • a renin inhibitor such as by way of example and preferably aliskiren, SPP-600 or SPP-800.
  • the compounds according to the invention are administered in combination with a mineralocorticoid receptor antagonist, such as by way of example and preferably spironolactone, eplerenone or finerenone.
  • a mineralocorticoid receptor antagonist such as by way of example and preferably spironolactone, eplerenone or finerenone.
  • the compounds according to the invention are administered in combination with a diuretic, such as by way of example and preferably furosemide, bumetanide, torsemide, bendroflumethiazide, chlorothiazide, hydrochlorothiazide, hydroflumethiazide, methyclothiazide, polythiazide, trichloromethiazide, chlorthalidone, indapamide, metolazone, quineth- azon, acetazolamide, dichlorophenamide, methazolamide, glycerol, isosorbide, mannitol, amiloride or triamterene.
  • a diuretic such as by way of example and preferably furosemide, bumetanide, torsemide, bendroflumethiazide, chlorothiazide, hydrochlorothiazide, hydroflumethiazide, methyclothiazide, polythiazide, trich
  • lipid metabolizing agents are preferably compounds from the group of CETP inhibitors, thyroid receptor agonists, cholesterol synthesis inhibitors such as HMG-CoA reductase or squalene synthesis inhibitors, the ACAT inhibitors, MTP inhibitors, PPAR alpha- , PPAR gamma and / or PPAR delta agonists, cholesterol absorption inhibitors, polymeric bile acid adsorbers, bile acid reabsorption inhibitors, lipase inhibitors and the lipoprotein (a) antagonists understood.
  • CETP inhibitors such as HMG-CoA reductase or squalene synthesis inhibitors
  • ACAT inhibitors such as HMG-CoA reductase or squalene synthesis inhibitors
  • MTP inhibitors MTP inhibitors
  • PPAR alpha- , PPAR gamma and / or PPAR delta agonists cholesterol absorption inhibitors
  • polymeric bile acid adsorbers bile acid rea
  • the compounds according to the invention are administered in combination with a CETP inhibitor, such as by way of example and preferably torcetrapib (CP-529 414), JJT-705 or CETP vaccine (Avant).
  • a CETP inhibitor such as by way of example and preferably torcetrapib (CP-529 414), JJT-705 or CETP vaccine (Avant).
  • the compounds according to the invention are administered in combination with a thyroid receptor agonist such as, by way of example and by way of preference, D-thyroxine, 3,5,3'-triiodothyronine (T3), CGS 23425 or axitirome (CGS 26214) ,
  • a thyroid receptor agonist such as, by way of example and by way of preference, D-thyroxine, 3,5,3'-triiodothyronine (T3), CGS 23425 or axitirome (CGS 26214)
  • the compounds according to the invention are administered in combination with an HMG-CoA reductase inhibitor from the class of statins, such as by way of example and preferably lovastatin, simvastatin, pravastatin, fluvastatin, atorvastatin, rosuvastatin or pitavastatin.
  • the compounds according to the invention are administered in combination with a squalene synthesis inhibitor, such as by way of example and
  • the compounds according to the invention are administered in combination with an ACAT inhibitor, such as by way of example and preferably avasimibe, melinamide, pactimibe, eflucimibe or SMP-797.
  • an ACAT inhibitor such as by way of example and preferably avasimibe, melinamide, pactimibe, eflucimibe or SMP-797.
  • the compounds according to the invention are administered in combination with an MTP inhibitor such as, for example and preferably, implitapide, BMS-201038, R-103757 or JTT-130.
  • an MTP inhibitor such as, for example and preferably, implitapide, BMS-201038, R-103757 or JTT-130.
  • the compounds according to the invention are administered in combination with a PPAR-gamma agonist, such as, by way of example and by way of preference, pioglitazone or rosiglitazone.
  • a PPAR-gamma agonist such as, by way of example and by way of preference, pioglitazone or rosiglitazone.
  • the compounds according to the invention are administered in combination with a PPAR delta agonist, such as by way of example and preferably GW 501516 or BAY 68-5042.
  • a PPAR delta agonist such as by way of example and preferably GW 501516 or BAY 68-5042.
  • the compounds according to the invention are administered in combination with a cholesterol absorption inhibitor, such as by way of example and preferably ezetimibe, tiqueside or pamaqueside.
  • the compounds according to the invention are administered in combination with a lipase inhibitor, such as, for example and preferably, orlistat.
  • a lipase inhibitor such as, for example and preferably, orlistat.
  • the compounds of the invention are administered in combination with a polymeric bile acid adsorbent such as, by way of example and by way of preference, cholestyramine, colestipol, colesolvam, cholesta gel or colestimide.
  • a polymeric bile acid adsorbent such as, by way of example and by way of preference, cholestyramine, colestipol, colesolvam, cholesta gel or colestimide.
  • the compounds according to the invention are administered in combination with a bile acid absorption inhibitor, by way of example and by way of example.
  • the compounds according to the invention are administered in combination with a lipoprotein (a) antagonist, such as by way of example and preferably gemcabene calcium (CI-1027) or nicotinic acid.
  • a lipoprotein (a) antagonist such as by way of example and preferably gemcabene calcium (CI-1027) or nicotinic acid.
  • compositions according to the invention with one or more further active compounds selected from the group consisting of corticosteroids, beta-adrenergic receptor agonists, anti-muscarcinogenic substances, PDE 4 inhibitors, PDE 5 inhibitors, sGC activators, sGC Stimulants, HNE inhibitors, prostacyclin analogs, endothelin antagonists, statins, antifibrotic agents, antiinflammatory agents, immunomodulating agents, immunosuppressive agents and cytotoxic agents.
  • further active compounds selected from the group consisting of corticosteroids, beta-adrenergic receptor agonists, anti-muscarcinogenic substances, PDE 4 inhibitors, PDE 5 inhibitors, sGC activators, sGC Stimulants, HNE inhibitors, prostacyclin analogs, endothelin antagonists, statins, antifibrotic agents, antiinflammatory agents, immunomodulating agents, immunosuppressive agents and cytotoxic agents.
  • compositions containing at least one compound of the invention usually together with one or more inert, non-toxic, pharmaceutically suitable excipients, and their use for the purposes mentioned above.
  • the compounds according to the invention can act systemically and / or locally.
  • they may be applied in a suitable manner, e.g. oral, parenteral, pulmonary, nasal, sublingual, lingual, buccal, rectal, dermal, transdermal, conjunctival, otic, or as an implant or stent.
  • the compounds according to the invention can be administered in suitable administration forms.
  • the compounds of the invention rapidly and / or modified donating application forms containing the compounds of the invention in crystalline and / or amorphized and / or dissolved form, such as tablets (uncoated or coated Tablets, for example with enteric or delayed-dissolving or insoluble coatings, which control the release of the compound according to the invention), tablets or films / wafers, films / lyophilisates, capsules (for example hard or soft gelatin capsules) which break quickly in the oral cavity, dragees, Granules, pellets, powders, emulsions, suspensions, aerosols or solutions.
  • tablets uncoated or coated Tablets, for example with enteric or delayed-dissolving or insoluble coatings, which control the release of the compound according to the invention
  • tablets or films / wafers films / lyophilisates
  • capsules for example hard or soft gelatin capsules
  • Parenteral administration can be done bypassing a resorption step (eg intravenously, intraarterially, intracardially, intraspinally or intralumbarly) or using absorption (for example by inhalation, intramuscularly, subcutaneously, intracutaneously, percutaneously or intraperitoneally).
  • a resorption step eg intravenously, intraarterially, intracardially, intraspinally or intralumbarly
  • absorption for example by inhalation, intramuscularly, subcutaneously, intracutaneously, percutaneously or intraperitoneally.
  • suitable application forms include injection and infusion preparations in the form of solutions, suspensions, emulsions, lyophilisates or sterile powders.
  • Inhalation medicaments including powder inhalers, nebulizers, metered dose aerosols
  • nasal drops solutions or sprays
  • lingual, sublingual or buccal tablets films / wafers or capsules
  • suppositories ear or ophthalmic preparations
  • vaginal capsules aqueous suspensions (lotions, shake mixtures)
  • lipophilic suspensions ointments
  • creams transdermal therapeutic systems (for example patches)
  • milk pastes, foams, scattering powders, implants or stents.
  • the compounds according to the invention can be converted into the stated administration forms. This can be done in a conventional manner by mixing with inert, non-toxic, pharmaceutically suitable excipients.
  • excipients for example microcrystalline cellulose, lactose, mannitol
  • solvents for example liquid polyethylene glycols
  • emulsifiers and dispersants or wetting agents for example sodium dodecyl sulfate, polyoxysorbitanoleate
  • binders for example polyvinylpyrrolidone
  • synthetic and natural polymers for example albumin
  • Stabilizers eg, antioxidants such as ascorbic acid
  • dyes eg, inorganic pigments such as iron oxides
  • flavor and / or odoriferous include, among others.
  • Excipients for example microcrystalline cellulose, lactose, mannitol
  • solvents for example liquid polyethylene glycols
  • emulsifiers and dispersants or wetting agents for example sodium dodecy
  • the dosage is about 0.01 to 100 mg kg, preferably about 0.01 to 20 mg / kg and most preferably 0.1 to 10 mg / kg body weight.
  • the amount is generally about 0.1 to 50 mg per inhalation.
  • Purity specifications usually refer to corresponding peak integrations in the LC / MS chromatogram, but may additionally have been determined with the help of the--NMR spectrum. If no purity is specified, it is usually one 100% purity according to automatic peak integration in the LC / MS chromatogram or purity was not explicitly determined.
  • the residue was added with 500 ml of water and 500 ml of ethyl acetate, and the phases were separated.
  • the aqueous phase was extracted once with 500 ml of ethyl acetate, and the combined organic phases were washed once with 1 liter of saturated sodium chloride solution, dried over sodium sulfate, filtered and concentrated.
  • the residue was mixed with about 200 ml ieri.-butyl methyl ether and stirred over the weekend. The solid which was present was filtered off and washed twice with 100 ml each of ethyl-butyl methyl ether.
  • the aqueous phase was extracted with 100 ml Efhyl- acetate, and the combined organic phases were washed once with 300 ml of saturated sodium chloride solution, dried over sodium sulfate, filtered and concentrated to a volume of about 70 ml. After cooling to 0 ° C. for 30 min, the solid formed was filtered off and washed twice with 5 ml of ethyl acetate each time. After drying in vacuo, 4.65 g (74% of theory) of a first batch of the title compound were obtained.
  • Example 7A (+/-) - di-tert-butyl- (2-oxo-2- ⁇ 4- [2- (tetrahydro-2-pyran-2-yloxy) -ethoxy] -phenyl ⁇ -ethyl) ⁇ 2- [4 oxo-6- (trifluoromethyl) -1,3,3-benzotriazine-3 (4 /) -yl] ethyl ⁇ malonate
  • Example 1 Exemplary embodiments: Example 1
  • the potency of the compounds of the invention compared to HME is determined in a in vi tro-inhibited st.
  • the HME-mediated amidolytic cleavage of a suitable peptide substrate results here in a fluorescence light increase.
  • the signal intensity of the fluorescent light is directly proportional to the enzyme activity.
  • the effective concentration of a test compound, at Half of the enzyme is inhibited (50% signal intensity of the fluorescent light) is given as IC 5 o value.
  • test buffer 0.1 M HEPES pH 7.4, 0.15M NaCl, 0.03M CaCl, 0.004 mM ZnCk, 0.02M EDTA, 0.005% Brij ®
  • the enzyme 0.5 nM HME, R & D Systems, 917-MP, autocatalytic activation according to the manufacturer's instructions
  • the intramolecularly quenched substrate [5 ⁇ M Mca-Pro-Leu-Gly-Leu-Glu-Glu-Ala-Dap (Dnp) -NH 2 ; Bachem, M-2670] in the presence and absence of the test substance (as a solution in DMSO) for two hours at 37 ° C incubated.
  • the fluorescent light intensity of the test mixtures is measured (excitation 323 nm, emission 393 nm).
  • the IC 50 values are determined by plotting the fluorescent light intensity versus the drug concentration.
  • a modified test is used for their more precise determination.
  • a ten-fold lower enzyme concentration is used (final concentration, for example, 0.05 nM) in order to achieve an increased sensitivity of the test.
  • the incubation time of the test is chosen to be longer (e.g., 16 hours).
  • This test corresponds to the standard HME inhibition test described above, but using a modified reaction buffer.
  • This reaction buffer additionally contains bovine serum albumin (BSA, fatty acid free, A6003, Sigma-Aldrich) of a final concentration of 2% (w / w), which corresponds approximately to half of the physiological serum albumin content.
  • BSA bovine serum albumin
  • the enzyme concentration in this modified assay is slightly elevated (e.g., 0.75 nM), as is the incubation time (e.g., three hours).
  • Table 1 shows for individual embodiments of the invention the IC 50 values from the standard or highly sensitive HME inhibition test (in part as averages of several independent individual determinations and rounded to two significant digits): Table 1: Inhibition of human macrophage elastase (HME / hMMP-12)
  • the potency of the compounds of the invention over other MMPs is also determined in vz 'iro inhibition assays.
  • the MMP-mediated amidolytic cleavage of a suitable peptide substrate also leads here to a fluorescence light increase.
  • the signal intensity of the fluorescent light is directly proportional to the enzyme activity.
  • the effective concentration of a test compound in which half of the enzyme is inhibited (50% signal intensity of the fluorescent light) is given as IC 50 value.
  • Recombinant MMP-1 (R & D Systems, 901-MP) is chemically activated according to the manufacturer's instructions by using APMA.
  • activated enzyme final concentration eg 2 nM
  • reaction buffer 50 mM Tris / HCl pH 7.5, 10 mM CaCl 2 , 150 mM NaCl, 0.05% Brij ® -35
  • 1 ⁇ of the test compound to be tested (as a solution in DMSO, suitable concentrations eg 1 nM to 30 ⁇ ) in a white 384-well microtiter plate (MTP) pipetted.
  • MTP white 384-well microtiter plate
  • the enzymatic reaction is started by adding the intramolecularly quenched substrate Mca Pro-Leu-Gly-Leu-Dpa (Dnp) -Ala-Arg-NH 2 (final concentration eg 10 ⁇ ; R & D Systems, ES-001) Total test volume of 50 ⁇ results.
  • the course of the MMP-1 reaction tion is measured by measuring the fluorescence intensity (excitation 320 nm, emission 410 nm) over a suitable period of time (eg over 120 minutes at a temperature of 32 ° C.).
  • Recombinant MMP-2 (R & D Systems, 902-MP) is chemically activated according to the manufacturer's instructions by using APMA.
  • activated enzyme final concentration eg 2 nM
  • reaction buffer 50 mM Tris / HCl pH 7.5, 10 mM CaCl 2 , 150 mM NaCl, 0.05% Brij ® -35
  • 1 ⁇ of the test compound to be tested (as a solution in DMSO, suitable concentrations eg 1 nM to 30 ⁇ ) in a white 384-well microtiter plate (MTP) pipetted.
  • MTP white 384-well microtiter plate
  • the enzymatic reaction is started by adding the intramolecularly quenched substrate Mca Pro-Leu-Gly-Leu-Dpa (Dnp) -Ala-Arg-NH 2 (final concentration eg 10 ⁇ ; R & D Systems, ES-001) Total test volume of 50 ⁇ results.
  • the course of the MMP-2 reaction is measured by measuring the fluorescence intensity (excitation 320 nm, emission 410 nm) over a suitable period of time (for example over 120 minutes at a temperature of 32 ° C.).
  • Recombinant MMP-3 (R & D Systems, 513-MP) is chemically activated according to the manufacturer's instructions by using APMA.
  • activated enzyme final concentration eg 2 nM
  • reaction buffer 50 mM Tris / HCl pH 7.5, 10 mM CaCl 2 , 150 mM NaCl, 0.05% Brij ® -35
  • 1 ⁇ of the test compound to be tested (as a solution in DMSO, suitable concentrations eg 1 nM to 30 ⁇ ) in a white 384-well microtiter plate (MTP) pipetted.
  • MTP white 384-well microtiter plate
  • the enzymatic reaction is carried out by adding the intramolecularly quenched substrate McA-Arg-Pro-Lys-Pro-Val-Glu-Nval-Trp-Arg-Lys (Dnp) -NH 2 (final concentration eg 10 ⁇ ; R & D Systems, ES-002 ) so that a total test volume of 50 ⁇ results.
  • the course of the MMP-3 reaction is measured by measuring the fluorescence intensity (excitation 320 nm, emission 410 nm) over a suitable period of time (eg over 120 minutes at a temperature of 32 ° C.).
  • Recombinant MMP-7 (R & D Systems, 907-MP) is chemically activated according to the manufacturer's instructions by using APMA.
  • activated enzyme final concentration eg 0.5 nM
  • reaction buffer 50 mM Tris / HCl pH 7.5, 10 mM CaCl 2 , 150 mM NaCl, 0.05% Brij ® -35
  • 1 ⁇ of the test compound to be tested (as a solution in DMSO, suitable concentrations eg 1 nM to 30 ⁇ ) in a white 384-well microtiter plate (MTP) pipetted.
  • MTP white 384-well microtiter plate
  • the enzymatic reaction is started by adding the intramolecularly quenched substrate Mca-Pro-Leu-Gly-Leu-Dpa (Dnp) -Ala-Arg-NH 2 (final concentration eg 10 ⁇ ; R & D Systems, ES-001) Total test volume of 50 ⁇ results.
  • the course of the MMP-7 Reaction is measured by measuring the fluorescence intensity (excitation 320 nm, emission 410 nm) over a suitable period of time (eg over 120 minutes at a temperature of 32 ° C.).
  • Recombinant MMP-8 (R & D Systems, 908-MP) is chemically activated according to the manufacturer's instructions by using APMA.
  • activated enzyme final concentration eg 0.5 nM
  • reaction buffer 50 mM Tris / HCl pH 7.5, 10 mM CaCl 2 , 150 mM NaCl, 0.05% Brij ® -35
  • 1 ⁇ of the test compound to be tested (as a solution in DMSO, suitable concentrations eg 1 nM to 30 ⁇ ) in a white 384-well microtiter plate (MTP) pipetted.
  • MTP white 384-well microtiter plate
  • the enzymatic reaction is started by adding the intramolecularly quenched substrate Mca-Pro-Leu-Gly-Leu-Dpa (Dnp) -Ala-Arg-NH 2 (final concentration eg 10 ⁇ ; R & D Systems, ES-001) Total test volume of 50 ⁇ results.
  • the course of the MMP-8 reaction is measured by measuring the fluorescence intensity (excitation 320 nm, emission 410 nm) over a suitable period of time (eg over 120 minutes at a temperature of 32 ° C.).
  • Recombinant MMP-9 (R & D Systems, 911-MP) is chemically activated according to the manufacturer's instructions by using APMA.
  • activated enzyme final concentration eg 0.1 nM
  • reaction buffer 50 mM Tris / HCl pH 7.5, 10 mM CaCl 2 , 150 mM NaCl, 0.05% Brij ® -35
  • 1 ⁇ of the test compound to be tested (as a solution in DMSO, suitable concentrations eg 1 nM to 30 ⁇ ) in a white 384-well microtiter plate (MTP) pipetted.
  • MTP white 384-well microtiter plate
  • the enzymatic reaction is started by adding the intramolecularly quenched substrate Mca-Pro-Leu-Gly-Leu-Dpa (Dnp) -Ala-Arg-NH 2 (final concentration eg 10 ⁇ ; R & D Systems, ES-001) Total test volume of 50 ⁇ results.
  • the course of the MMP-9 reaction is measured by measuring the fluorescence intensity (excitation 320 nm, emission 410 nm) over a suitable period of time (for example over 120 minutes at a temperature of 32 ° C.).
  • Recombinant MMP-10 (R & D Systems, 910-MP) is chemically activated according to the manufacturer's instructions by using APMA.
  • activated enzyme final concentration eg 2 nM
  • reaction buffer 50 mM Tris / HCl pH 7.5, 10 mM CaCl 2 , 150 mM NaCl, 0.05% Brij ® -35
  • 1 ⁇ of the test compound to be tested (as a solution in DMSO, suitable concentrations eg 1 nM to 30 ⁇ ) in a white 384-well microtiter plate (MTP) pipetted.
  • MTP white 384-well microtiter plate
  • Arg-Pro-Lys-Pro-Val-Glu-Nval-Trp-Arg-Lys (Dnp) -NH 2 (final concentration eg 10 ⁇ ; R & D Systems, ES-002) is started, resulting in a total test volume of 50 ⁇ .
  • the course of the MMP-10 reaction is measured by measuring the fluorescence intensity (excitation 320 nm, emission 410 nm) over a suitable period of time (for example over a period of 120 minutes at a temperature of 32 ° C.).
  • Recombinant MMP-13 (R & D Systems, 511-MP) is chemically activated according to the manufacturer's instructions by using APMA.
  • activated enzyme final concentration eg 0.1 nM
  • reaction buffer 50 mM Tris / HCl pH 7.5, 10 mM CaCl 2 , 150 mM NaCl, 0.05% Brij ® -35
  • 1 ⁇ of the test compound to be tested (as a solution in DMSO, suitable concentrations eg 1 nM to 30 ⁇ ) in a white 384-well microtiter plate (MTP) pipetted.
  • MTP white 384-well microtiter plate
  • the enzymatic reaction is started by adding the intramolecularly quenched substrate Mca-Pro-Leu-Gly-Leu-Dpa (Dnp) -Ala-Arg-NH 2 (final concentration eg 10 ⁇ ; R & D Systems, ES-001) Total test volume of 50 ⁇ results.
  • the course of the MMP-13 reaction is measured by measuring the fluorescence intensity (excitation 320 nm, emission 410 nm) over a suitable period of time (eg over 120 minutes at a temperature of 32 ° C.).
  • Recombinant MMP-14 (R & D Systems, 918-MP) is enzymatically activated according to the manufacturer's instructions by using recombinant furin (R & D Systems, 1503-SE).
  • activated enzyme final concentration eg 0.5 nM
  • reaction buffer 50 mM Tris / HCl pH 7.5, 10 mM CaCh, 150 mM NaCl, 0.05% Brij ® -35
  • 1 ⁇ of the test compound to be tested (as a solution in DMSO , suitable concentrations eg 1 nM to 30 ⁇ ) in a white 384-well microtiter plate (MTP) pipetted.
  • MTP white 384-well microtiter plate
  • the enzymatic reaction is started by addition of the intramolecularly quenched substrate Mca-Lys-Pro-Leu-Gly-Leu-Dpa (Dnp) -Ala-Arg-NH2 (final concentration eg 5 ⁇ ; R & D Systems, ES-010). so that a total test volume of 50 ⁇ results.
  • the course of the MMP-14 reaction is measured by measuring the fluorescence intensity (excitation 320 nm, emission 410 nm) over a suitable period of time (eg over 120 minutes at a temperature of 32 ° C.).
  • In vitro ⁇ -16 inhibition test :
  • Recombinant MMP-16 (R & D Systems, 1785-MP) is enzymatically activated according to the manufacturer's instructions by using recombinant furin (R & D Systems, 1503-SE).
  • activated enzyme final concentration eg 1 nM
  • reaction buffer 50 mM Tris / HCl pH 7.5, 10 mM CaCl 2 , 150 mM NaCl, 0.05% Brij ® -35
  • Compound (as a solution in DMSO, suitable concentrations eg 1 nM to 30 ⁇ ) in a white 384-well microtiter plate (MTP) pipetted.
  • the enzymatic reaction is started by addition of the intramolecularly quenched substrate Mca-Lys-Pro-Leu-Gly-Leu-Dpa (Dnp) -Ala-Arg-NH2 (final concentration eg 5 ⁇ ; R & D Systems, ES-010) a total test volume of 50 ⁇ results.
  • the course of the MMP-16 reaction is measured by measuring the fluorescence intensity (excitation 320 nm, emission 410 nm) over a suitable period of time (for example over 120 minutes at a temperature of 32 ° C.).
  • Recombinant mouse MMP-2 (R & D Systems, 924-MP) is chemically activated according to the manufacturer's instructions by using APMA.
  • activated enzyme final concentration eg 0.1 nM
  • reaction buffer 50 mM Tris / HCl pH 7.5, 10 mM CaCl 2 , 150 mM NaCl, 0.05% Brij ® -35
  • 1 ⁇ of the test compound to be tested (as a solution in DMSO, suitable concentrations eg 1 nM to 30 ⁇ ) in a white 384-well microtiter plate (MTP) pipetted.
  • MTP white 384-well microtiter plate
  • the enzymatic reaction is started by addition of the intramolecularly quenched substrate Mca-Pro-Leu-Gly-Leu-Dpa (Dnp) -Ala-Arg-NH 2 (final concentration eg 10 ⁇ ; R & D Systems, ES-001) that a total test volume of 50 ⁇ results.
  • the course of the MMP-2 reaction is measured by measuring the fluorescence intensity (excitation 320 nm, emission 410 nm) over a suitable period of time (eg over 120 minutes at a temperature of 32 ° C.).
  • In vitro MMP-3 inhibition test of the mouse In vitro MMP-3 inhibition test of the mouse:
  • Recombinant mouse MMP-3 (R & D Systems, 548-MP) is chemically activated according to the manufacturer's instructions by using APMA.
  • activated enzyme final concentration eg 0.5 nM
  • reaction buffer 50 mM Tris / HCl pH 7.5, 10 mM CaCl 2 , 150 mM NaCl, 0.05% Brij ® -35
  • 1 ⁇ of the test compound to be tested (as a solution in DMSO, suitable concentrations eg 1 nM to 30 ⁇ ) in a white 384-well microtiter plate (MTP) pipetted.
  • MTP white 384-well microtiter plate
  • the enzymatic reaction is carried out by addition of the intramolecularly quenched substrate Mca-Arg-Pro-Lys-Pro-Val-Glu-Nval-Trp-Arg-Lys (Dnp) -NH2 (final concentration eg 5 ⁇ ; R & D Systems, ES-002) so that a total test volume of 50 ⁇ results.
  • the course of the MMP-3 reaction is determined by measuring the fluorescence intensity (excitation 320 nm, Emission 410 nm) over a suitable period of time (eg over 120 minutes at a temperature of 32 ° C).
  • Recombinant mouse MMP-7 (R & D Systems, 2967-MP) is chemically activated according to the manufacturer's instructions by using APMA.
  • activated enzyme final concentration eg 0.5 nM
  • reaction buffer 50 mM Tris / HCl pH 7.5, 10 mM CaCl 2 , 150 mM NaCl, 0.05% Brij ® -35
  • 1 ⁇ of the test compound to be tested (as a solution in DMSO, suitable concentrations eg 1 nM to 30 ⁇ ) in a white 384-well microtiter plate (MTP) pipetted.
  • MTP white 384-well microtiter plate
  • the enzymatic reaction is started by addition of the intramolecularly quenched substrate Mca-Lys-Pro-Leu-Gly-Leu-Dpa (Dnp) -Ala-Arg-NH2 (final concentration eg 5 ⁇ ; R & D Systems, ES-010) a total test volume of 50 ⁇ results.
  • the course of the MMP-7 reaction is measured by measuring the fluorescence intensity (excitation 320 nm, emission 410 nm) over a suitable period of time (eg over 120 minutes at a temperature of 32 ° C.).
  • In vitro MMP-8 inhibition test of the mouse In vitro MMP-8 inhibition test of the mouse:
  • Recombinant mouse MMP-8 (R & D Systems, 2904-MP) is chemically activated according to the manufacturer's instructions by using APMA.
  • activated enzyme final concentration eg 2 nM
  • reaction buffer 50 mM Tris / HCl pH 7.5, 10 mM CaCl 2 , 150 mM NaCl, 0.05% Brij ® -35
  • 1 ⁇ of the test compound to be tested (as a solution in DMSO, suitable concentrations eg 1 nM to 30 ⁇ ) in a white 384-well microtiter plate (MTP) pipetted.
  • MTP white 384-well microtiter plate
  • the enzymatic reaction is started by addition of the intramolecularly quenched substrate Mca-Lys-Pro-Leu-Gly-Leu-Dpa (Dnp) -Ala-Arg-NH2 (final concentration eg 5 ⁇ ; R & D Systems, ES-010) a total test volume of 50 ⁇ results.
  • the course of the MMP-8 reaction is measured by measuring the fluorescence intensity (excitation 320 nm, emission 410 nm) over a suitable period of time (for example over 120 minutes at a temperature of 32 ° C.).
  • Recombinant mouse MMP-9 (R & D Systems, 909-MP) is chemically activated according to the manufacturer's instructions by using APMA.
  • activated enzyme final concentration eg 0.1 nM
  • reaction buffer 50 mM Tris / HCl pH 7.5, 10 mM CaCl 2 , 150 mM NaCl, 0.05% Brij ® -35
  • 1 ⁇ of the test compound to be tested (as a solution in DMSO, suitable concentrations eg 1 nM to 30 ⁇ ) in a white 384-well microtiter plate (MTP) pipetted.
  • MTP white 384-well microtiter plate
  • the enzymatic reaction is carried out by addition of the intramolecularly quenched substrate Mca-Pro-Leu-Gly-Leu-Dpa (Dnp) -Ala-Arg-NH 2 (final concentration eg 5 ⁇ ; R & D Systems, ES-001), resulting in a total test volume of 50 ⁇ .
  • the course of the MMP-9 reaction is measured by measuring the fluorescence intensity (excitation 320 nm, emission 410 nm) over a suitable period of time (eg over 120 minutes at a temperature of 32 ° C.).
  • In vitro ⁇ -12 inhibition test of the mouse In vitro ⁇ -12 inhibition test of the mouse:
  • Recombinant mouse MMP-12 (R & D Systems, 3467-MP) is autocatalytically activated according to the manufacturer's instructions.
  • activated enzyme final concentration eg 1 nM
  • reaction buffer 50 mM Tris / HCl pH 7.5, 10 mM CaCl 2 , 150 mM NaCl, 0.05% Brij ® -35
  • 1 ⁇ of the test compound to be tested (as a solution in DMSO, suitable concentrations eg 1 nM to 30 ⁇ ) in a white 384-well microtiter plate (MTP) pipetted.
  • MTP white 384-well microtiter plate
  • the enzymatic reaction is started by addition of the intramolecularly quenched substrate Mca-Lys-Pro-Leu-Gly-Leu-Dpa (Dnp) -Ala-Arg-NH 2 (final concentration eg 5 ⁇ ; R & D Systems, ES-010) that a total test volume of 50 ⁇ results.
  • the course of the MMP-12 reaction is measured by measuring the fluorescence intensity (excitation 320 nm, emission 410 nm) over a suitable period of time (for example over 120 minutes at a temperature of 32 ° C.).
  • a modified test is used for more precise determination.
  • a tenfold lower enzyme concentration is used (final concentration, for example, 0.1 nM) in order to achieve an increased sensitivity of the test.
  • the incubation time of the test is chosen to be longer (e.g., 16 hours).
  • Recombinant rat MMP-2 (R & D Systems, 924-MP) is chemically activated according to the manufacturer's instructions by using APMA.
  • activated enzyme final concentration eg 0.1 nM
  • reaction buffer 50 mM Tris / HCl pH 7.5, 10 mM CaCh, 150 mM NaCl, 0.05% Brij ® -35
  • 1 ⁇ of the test compound to be tested (as a solution in DMSO , suitable concentrations eg 1 nM to 30 ⁇ ) in a white 384-well microtiter plate (MTP) pipetted.
  • MTP white 384-well microtiter plate
  • the enzymatic reaction is started by adding the intramolecularly quenched substrate Mca-Pro-Leu-Gly-Leu-Dpa (Dnp) -Ala-Arg-NH 2 (final concentration eg 10 ⁇ ; R & D Systems, ES-001) Total test volume of 50 ⁇ results.
  • the course of the MMP-2 reaction is measured by measuring the fluorescence intensity (excitation 320 nm, emission 410 nm) over a suitable period of time (eg over 120 minutes at a temperature of 32 ° C.).
  • Rat in vitro MMP-8 inhibition test :
  • Recombinant rat MMP-8 (R & D Systems, 3245-MP) is chemically activated according to the manufacturer's instructions by using APMA.
  • activated enzyme final concentration eg 2 nM
  • reaction buffer 50 mM Tris / HCl pH 7.5, 10 mM CaCh, 150 mM NaCl, 0.05% Brij ® -35
  • 1 ⁇ of the test compound to be tested (as a solution in DMSO , suitable concentrations eg 1 nM to 30 ⁇ ) in a white 384-well microtiter plate (MTP) pipetted.
  • MTP white 384-well microtiter plate
  • the enzymatic reaction is started by addition of the intramolecularly quenched substrate Mca-Lys-Pro-Leu-Gly-Leu-Dpa (Dnp) -Ala-Arg-NH2 (final concentration eg 5 ⁇ ; R & D Systems, ES-010) a total test volume of 50 ⁇ results.
  • the course of the MMP-8 reaction is measured by measuring the fluorescence intensity (excitation 320 nm, emission 410 nm) over a suitable period of time (for example over 120 minutes at a temperature of 32 ° C.).
  • Recombinant mouse MMP-9 (R & D Systems, 5427-MM) is chemically activated according to the manufacturer's instructions by using APMA.
  • activated enzyme final concentration eg 0.1 nM
  • reaction buffer 50 mM Tris / HCl pH 7.5, 10 mM CaCl 2 , 150 mM NaCl, 0.05% Brij ® -35
  • 1 ⁇ of the test compound to be tested (as a solution in DMSO, suitable concentrations eg 1 nM to 30 ⁇ ) in a white 384-well microtiter plate (MTP) pipetted.
  • MTP white 384-well microtiter plate
  • the enzymatic reaction is started by adding the intramolecularly quenched substrate Mca-Pro-Leu-Gly-Leu-Dpa (Dnp) -Ala-Arg-NH 2 (final concentration eg 5 ⁇ ; R & D Systems, ES-001) Total test volume of 50 ⁇ results.
  • the course of the MMP-9 reaction is measured by measuring the fluorescence intensity (excitation 320 nm, emission 410 nm) over a suitable period of time (eg over 120 minutes at a temperature of 32 ° C.).
  • In vitro ⁇ -12 inhibition test of the rat In vitro ⁇ -12 inhibition test of the rat:
  • Rat MMP-12 (Uniprot NP_446415.1; construct L96-V277) is expressed with an additional N-terminal His tag and a TEV consecutive cleavage sequence using a pDEco7 vector in E. coli (BL21).
  • the recombinantly expressed protein forms an intracellular insoluble protein complex (so-called inclusion body). This is solubilized after separation and intensive washing under denaturing conditions.
  • inclusion body pellet fraction from a 250 ml E. coli culture in a volume of 120 ml buffer A (50 mM Tris pH 7.4, 100 mM NaCl, 0.03 mM ZnCh, 10 mM CaCh, 8 M urea).
  • the soluble protein is renatured by dialysing each 60 ml of the sample several times at 4-8 ° C against buffer B (50 mM Tris pH 7.4, 100 mM NaCl, 0.03 mM ZnCl 2 , 10 mM CaCl 2 ). After dialysis the sample is centrifuged (25,000 xg). The refolded protein is in the supernatant with a yield of 3.7 mg per 250 ml-E. coli culture. The protein thus obtained is enzymatically active without further purification operations or protease-mediated cleavage processes.
  • MMP-12 protein final concentration, for example 1 nM
  • reaction buffer 50 mM Tris / HCl pH 7.5, 10 mM CaCl 2, 150 mM NaCl, 0.05% Brij ® -35
  • concentrations eg 1 nM to 30 ⁇ in a white 384-well microtiter plate (MTP) pipetted.
  • the enzymatic reaction is started by addition of the intramolecular quenched substrate Mca-Pro-Leu-Gly-Leu-Dpa (Dnp) -Ala-Arg-NH2 (final concentration eg 5 ⁇ ; R & D Systems, ES-001), giving a total assay volume of 50 ⁇ results.
  • the course of the MMP-12 reaction is measured by measuring the fluorescence intensity (excitation 320 nm, emission 410 nm) over a suitable period of time (for example over 120 minutes at a temperature of 32 ° C.).
  • Table 3 shows representative IC 50 values from mouse MMP inhibition assays (in part as averages of several independent determinations and rounded to two significant digits) for representative embodiments of the invention:
  • the compounds according to the invention thus have a high inhibitory potency against mouse MMP-12 and at the same time a high selectivity (usually one to three orders of magnitude) over related murine MMPs.
  • Elastase-induced pulmonary emphysema in mouse, rat or hamster is a widely used animal model of pulmonary emphysema [The Fas / Fas-ligand pathway does not mediate the apoptosis in elastase-induced emphysema in mice, Sawada et al., Exp. Lung Res. 33, 277-288 (2007)].
  • the animals receive orotracheal instillation of porcine pancreatic elastase.
  • the treatment of the animals with the test substance begins on the day of instillation of the porcine pancreatic elastase and extends over a period of 3 weeks. At the end of the study, lung compliance is determined and alveolar morphometry performed.
  • Mouse, rat, or hamster-induced lung induced fibrosis is a widely used animal model of pulmonary fibrosis in mice, Shimbori et al., Exp. Lung Res. 36, 292-301 (2010) )].
  • the animals receive an orotracheal instillation of silica.
  • the treatment of the animals with the test substance starts on the day of the instillation of the silica or therapeutically one week later and extends over a period of 6 weeks.
  • a bronchioalveolar lavage is performed to determine cell content and biomarkers, and a histological assessment of pulmonary fibrosis is performed.
  • the ability of substances to inhibit the CYP enzymes CYP1A2, CYP2C9, CYP2D6 and CYP3A4 in humans is investigated using pooled human liver microsomes as the enzyme source in the presence of standard substrates (see below) that form CYP-specific metabolites.
  • the inhibition effects are observed at six different concentrations of the test compounds. [2.8, 5.6, 8.3, 16.7, 20 (or 25) and 50 ⁇ ], was compared with the extent of CYP-specific metabolite formation of the standard substrates in the absence of the test compounds and the corresponding IC 50 values were calculated.
  • a standard inhibitor that specifically inhibits a single CYP isoform is always incubated to make results comparable between different series.
  • test compounds are preferably dissolved in acetonitrile.
  • 96-well plates are incubated for a defined time at 37 ° C with pooled human liver microsomes. The reactions are stopped by addition of 100 ⁇ L acetonitrile, which is a suitable internal standard. Precipitated proteins are separated by centrifugation, the supernatants are pooled and analyzed by LC-MS / MS.
  • the metabolic stability of test compounds to hepatocytes is determined by incubating the compounds at low concentrations (preferably below or around 1 ⁇ ) and at low cell counts (preferably at 1 ⁇ 10 6 cells / ml) in order to obtain linear kinetic conditions in the Try to make sure. Seven samples from the incubation solution are taken at a fixed time interval for LC-MS analysis to determine the half-life (ie, degradation) of each compound. From this half-life different "clearance” parameters (CL) and "Fmax” values are calculated (see below). The CL and Fmax values are a measure of the phase I and phase 2 metabolism of the compounds in the hepatocytes. In order to minimize the influence of the organic solvent on the enzymes in the incubation approaches, its concentration generally becomes apparent 1% (acetonitrile) or 0.1% (DMSO) limited.
  • hepatocyte cell count in the liver 1.1 * 10 8 cells / g liver is expected.
  • CL parameters based on half-lives much longer than the incubation period typically 90 minutes can only be considered as rough guidelines.
  • Table 4 shows, for representative embodiments of the invention, the CL and Fmax values from this assay after incubation of the compounds with rat hepatocytes (partly as averages of several independent individual determinations):
  • the compounds according to the invention are incubated with liver microsomes or with primary fresh hepatocytes of various animal species (eg rat, dog) as well as of human origin in order to obtain information on the most complete hepatic phase I and phase II metabolism and on the Obtain and compare enzymes involved in metabolism.
  • the compounds of the invention are incubated at a concentration of about 1-10 ⁇ .
  • stock solutions of the compounds are prepared at a concentration of 0.1-1 mM in acetonitrile and then pipetted with a 1: 100 dilution in the incubation mixture.
  • the liver microsomes are incubated in 50 mM potassium phosphate buffer pH 7.4 with and without NADPH-generating system consisting of 1 mM NADP + , 10 mM glucose-6-phosphate and 1 unit glucose-6-phosphate dehydrogenase at 37 ° C.
  • Primary hepatocytes are also incubated in suspension in William's E medium at 37 ° C. After an incubation period of 0-4 h, the incubation mixtures are stopped with acetonitrile (final concentration about 30%) and the protein is centrifuged off at about 15,000 ⁇ g. The thus stopped samples are either analyzed directly or stored at -20 ° C until analysis.
  • the analysis is carried out by means of high performance liquid chromatography with ultraviolet and mass spectrometric detection (HPLC-UV-MS / MS).
  • HPLC-UV-MS / MS ultraviolet and mass spectrometric detection
  • the supernatants of the incubation samples are chromatographed with suitable C18 reverse phase columns and variable eluent mixtures of acetonitrile and 10 mM aqueous ammonium formate solution or 0.05% aqueous formic acid.
  • the UV chromatograms in combination with the mass spectrometric data serve to identify, structure elucidate and quantitatively estimate the metabolites and to quantitatively determine the metabolic decrease of the compounds according to the invention in the incubation mixtures.
  • the substance to be tested is administered intravenously to rats or mice as a solution (eg in appropriate plasma with a small amount of DMSO or in a PEG / ethanolAmerge mixture), the oral administration is carried out as a solution (eg in Solutol / EthanolAer - or PEG / ethanol / water mixtures) or as a suspension (eg in Tylose) each via a gavage.
  • a solution eg in Solutol / EthanolAer - or PEG / ethanol / water mixtures
  • a suspension eg in Tylose
  • the pharmacokinetic parameters are calculated using an internal standard and with the aid of a validated computer program, such as AUC (area under the concentration-time curve), Cmax (maximum plasma concentration), tm (half-life), Vss (distribution volume) and CL (clearance) and the absolute and relative bioavailability F and F re i (iv / po comparison or comparison of suspension to solution after po administration).
  • AUC area under the concentration-time curve
  • Cmax maximum plasma concentration
  • tm half-life
  • Vss distributed volume
  • CL yield
  • the compounds according to the invention can be converted into pharmaceutical preparations as follows:
  • composition
  • the mixture of compound of the invention, lactose and starch is granulated with a 5% solution (m / m) of the PVP in water.
  • the granules are mixed after drying with the magnesium stearate for 5 minutes.
  • This mixture is compressed with a conventional tablet press (for the tablet format see above).
  • a pressing force of 15 kN is used as a guideline for the compression.
  • the rhodigel is suspended in ethanol, the compound according to the invention is added to the suspension. While stirring, the addition of water. Until the completion of the swelling of Rhodigels is stirred for about 6 h.
  • the compound of the invention is suspended in the mixture of polyethylene glycol and polysorbate with stirring. The stirring is continued until complete dissolution of the compound according to the invention.
  • i.v. solution The compound of the invention is dissolved at a concentration below the saturation solubility in a physiologically acceptable solvent (e.g., isotonic saline, glucose solution 5% and / or PEG 400 solution 30%). The solution is sterile filtered and filled into sterile and pyrogen-free injection containers.
  • a physiologically acceptable solvent e.g., isotonic saline, glucose solution 5% and / or PEG 400 solution 30%.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La présente invention concerne de nouveaux dérivés d'acide 4-(1,2,3-benzotriazin-4-on-3-yl)butyrique substitués, des procédés permettant de fabriquer lesdits dérivés, leur utilisation individuellement ou en combinaisons pour le traitement et/ou la prévention de maladies, ainsi que leur utilisation pour la fabrication de médicaments destinés au traitement et/ou à la prévention de maladies, en particulier destinés au traitement et/ou à la prévention de maladies des voies respiratoires, des poumons et du système cardiovasculaire.
PCT/EP2015/056986 2014-04-03 2015-03-31 Acides benzotriazinonebutyriques substitués et leur utilisation Ceased WO2015150364A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP14163305.7 2014-04-03
EP14163305 2014-04-03

Publications (1)

Publication Number Publication Date
WO2015150364A1 true WO2015150364A1 (fr) 2015-10-08

Family

ID=50397041

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2015/056986 Ceased WO2015150364A1 (fr) 2014-04-03 2015-03-31 Acides benzotriazinonebutyriques substitués et leur utilisation

Country Status (1)

Country Link
WO (1) WO2015150364A1 (fr)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017106175A2 (fr) 2015-12-14 2017-06-22 Ironwood Pharmaceuticals, Inc. Utilisation de stimulateurs de la sgc pour le traitement d'un dysfonctionnement du sphincter gastro-intestinal
WO2018111795A2 (fr) 2016-12-13 2018-06-21 Ironwood Pharmaceuticals, Inc. Utilisation de stimulateurs de sgc pour le traitement de la motilité œsophagienne
WO2020014504A1 (fr) 2018-07-11 2020-01-16 Cyclerion Therapeutics, Inc. Utilisation de stimulateurs gcs pour le traitement de maladies mitochondriales
WO2021055725A1 (fr) * 2019-09-20 2021-03-25 Reneo Pharmaceuticals, Inc. Utilisation d'un agoniste ppar-delta dans le traitement de la maladie de dee

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997043237A1 (fr) * 1996-05-15 1997-11-20 Bayer Corporation Derives de l'acide 4-arylbutyrique substitue agissant comme inhibiteurs de la metalloprotease matricielle
WO2012014114A1 (fr) * 2010-07-30 2012-02-02 Ranbaxy Laboratories Limited Inhibiteurs de métalloprotéinase de matrice
WO2012038942A1 (fr) * 2010-09-24 2012-03-29 Ranbaxy Laboratories Limited Inhibiteurs de métalloprotéinase matricielle

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997043237A1 (fr) * 1996-05-15 1997-11-20 Bayer Corporation Derives de l'acide 4-arylbutyrique substitue agissant comme inhibiteurs de la metalloprotease matricielle
WO2012014114A1 (fr) * 2010-07-30 2012-02-02 Ranbaxy Laboratories Limited Inhibiteurs de métalloprotéinase de matrice
WO2012038942A1 (fr) * 2010-09-24 2012-03-29 Ranbaxy Laboratories Limited Inhibiteurs de métalloprotéinase matricielle

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017106175A2 (fr) 2015-12-14 2017-06-22 Ironwood Pharmaceuticals, Inc. Utilisation de stimulateurs de la sgc pour le traitement d'un dysfonctionnement du sphincter gastro-intestinal
WO2018111795A2 (fr) 2016-12-13 2018-06-21 Ironwood Pharmaceuticals, Inc. Utilisation de stimulateurs de sgc pour le traitement de la motilité œsophagienne
WO2020014504A1 (fr) 2018-07-11 2020-01-16 Cyclerion Therapeutics, Inc. Utilisation de stimulateurs gcs pour le traitement de maladies mitochondriales
WO2021055725A1 (fr) * 2019-09-20 2021-03-25 Reneo Pharmaceuticals, Inc. Utilisation d'un agoniste ppar-delta dans le traitement de la maladie de dee

Similar Documents

Publication Publication Date Title
EP2234985B1 (fr) 4-(4-cyano-2-thioaryle)-dihydropyrimidinone et son utilisation
EP2417112B1 (fr) Diaryldihydropyrimidinones à substitution sulfonamide et sulfoximine et leur utilisation
WO2015189117A1 (fr) Dérivés de l'acide 4-oxobutanoïque hétérobicycliques substitués et utilisation desdits dérivés
EP2285809B1 (fr) 1,4-diaryl-pyrimidopyridazin-2,5-diones et leur utilisation
DE102007061766A1 (de) 4-(4-Cyano-2-thioaryl)-dihydropyrimidinone und ihre Verwendung
AU2020257075B2 (en) Methods and agents for treating disease
US10117864B2 (en) Substituted N-bicyclo-2-aryl-quinolin-4-carboxamides and use thereof
EP3191452A1 (fr) N,2-diarylquinoline-4-carboxamides substitués et utilisation desdits n,2-diarylquinoline-4-carboxamides substitués comme anti-inflammatoires
EP3126358A1 (fr) Acides cyclopentanecarboxyliques à disubstitution 2,5 pour traiter des maladies des voies respiratoires
WO2015150364A1 (fr) Acides benzotriazinonebutyriques substitués et leur utilisation
EP3126340A2 (fr) Dérivés chiraux d'acide cyclopentanecarboxylique à disubstitution 2,5 et leur utilisation
EP3126339A1 (fr) Acides cyclopentanecarboxyliques à disubstitution 2,5 et leur utilisation
WO2015150366A1 (fr) Dérivés d'éthers phénoliques à substitutions cycliques et leur utilisation
EP3707141B1 (fr) 2,4-dihydro-3h-1,2,4-triazol-3-ones substituées et leur utilisation
DE102008052013A1 (de) 4-(4-Cyano-2-thioaryl)-dihydropyrimidinone und ihre Verwendung
DE102010030187A1 (de) 4-Cyan-2-sulfonylphenyl)pyrazolyl-substituierte Pyridinone und Pyrazinone und ihre Verwendung
HK1237347A1 (en) 2,5-disubstituted cyclopentane carboxylic acids for the treatment of respiratoy tract diseases

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 15712935

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 15712935

Country of ref document: EP

Kind code of ref document: A1